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Abstract 
Microglia are the primary cellular source of type I interferons (I-IFNs) in the brain upon neurotropic virus 
infection. Although the I-IFN-based antiviral innate immune response is crucial for eliminating viruses, 
overproduction led to immune disorders. Therefore, the relatively long-lasting I-IFNs must be precisely 
controlled, but the regulatory mechanism for the innate antiviral response in microglia remains largely 
unknown. Long non-coding RNAs (lncRNAs) are being recognized as crucial factors in numerous diseases, but 
their regulatory roles in the innate antiviral response in microglia are undefined. 
Methods: The high-throughput RNA sequencing was performed to obtain differentially expressed lncRNAs 
(DELs) in primary microglia infected with or without the neurotropic herpes simplex virus type 1 (HSV-1). We 
selected four DELs ranked in the top 15 in basic level and their fold change induced by HSV-1, i.e., 
FPKMHSV-1/FPKMCells.We subsequently found a key lncRNA affecting the innate antiviral response of microglia 
significantly. We next used dual-luciferase reporter assays, bioinformatical tools, and truncation mutants of 
both lncRNA and targeted proteins to elucidate the downstream and upstream mechanism of action of 
lncRNA. Further, we established microglia-specific knock-in (KI) mice to investigate the role of lncRNA in vivo. 
Results: We identified a long intergenic non-coding RNA, linc-AhRA, involved in regulating the innate antiviral 
response in murine microglia. linc-AhRA is activated by aryl hydrocarbon receptor (AhR) and restricts I-IFN 
production in microglia upon neurotropic herpesvirus infection and innate immune stimulation. 
Mechanistically, linc-AhRA binds to both tripartite motif-containing 27 (TRIM27) and TANK-binding kinase 1 
(TBK1) through its conserved 117nt fragment as a molecular scaffold to enhance TRIM27-TBK1 interaction. 
This interaction facilitates the TRIM27-mediated ubiquitination of TBK1 and results in 
ubiquitin-proteasome-dependent degradation of TBK1. Consequently, linc-AhRA suppresses I-IFN production 
through facilitating TBK1 degradation and limits the microglial innate immune response against neurotropic 
herpesvirus infection. Microglia-specific KI of linc-AhRA mice shows a weakened antiviral immune response 
upon neurotropic herpesvirus challenge due to a reduction of TBK1 in microglia. 
Conclusion: Our findings indicate that linc-AhRA is a negative regulator of I-IFN production in microglia to 
avoid excessive autoimmune responses. These findings uncover a previously unappreciated role for lncRNA 
conserved fragments in the innate antiviral response, providing a strong foundation for developing nucleotide 
drugs based on conserved functional fragments within lncRNAs. 











Virus-derived components can be recognized by 
pattern-recognition receptors (PRRs) within host cells, 
triggering the expression of type I interferons (I-IFNs) 
(IFN-α/β) via activation of the interferon regulatory 
factor 3 (IRF3) and nuclear factor-κB (NF-κB) 
signalling [1, 2]. I-IFNs act as autocrine and paracrine 
activators of I-IFN receptors to induce the expressions 
of numerous interferon-stimulated genes (ISGs) 
encoding a subset of antiviral proteins [3]. Microglia 
are the brain’s main cellular source of I-IFNs upon 
neurotropic virus infection [2, 4-6]. I-IFNs from 
microglia also orchestrate the antiviral defence to 
other cells in the CNS [1, 2, 7]. However, the excessive 
expression of I-IFNs has an overall detrimental effect 
on the CNS [1, 4, 6, 8]. Therefore, a systematic but 
flexible regulatory mechanism is required for 
microglia to balance I-IFN production and efficiently 
eliminate invading viruses while avoiding 
immunopathology. TANK-binding kinase 1 (TBK1) is 
a crucial factor that mediates the activation of IRF3, 
leading to the induction of IFN-α/β following viral 
infections [9]. TBK1 activity is tightly regulated by a 
variety of post-translational modifications (PTMs), 
such as phosphorylation, ubiquitination (Ubi), and 
the prevention of functional TBK1-containing 
complex formation [10-12]. The E3 ubiquitin ligase 
TRIM27 interacts with TBK1 and leads to 
Ubi-mediated degradation of TBK1, resulting in the 
suppression of IRF3 activation and IFN-α/β 
production [10, 13]. However, the intrinsic inhibition 
pathway for the IFN response may be leveraged by 
viruses. Therefore, a balance between the host innate 
antiviral response and virus immune evasion is 
pivotal to virus pathogenesis. Identification of the key 
molecules involved in microglia-neurotropic virus 
interactions contributes to a better understanding of 
the innate immune homeostasis in the CNS. Previous 
studies focused on the regulatory network in 
non-CNS macrophages but provided a limited 
understanding of the regulatory mechanism for the 
innate antiviral response in CNS. Herpes simplex 
virus type 1 (HSV-1) is the most common human 
neurotropic viruses, infection of which causes 
numerous diseases, including herpes simplex 
encephalitis (HSE) that has a high mortality rate if left 
untreated, and herpetic stromal keratitis (HSK) is the 
leading cause of infectious blindness [14, 15]. 
Moreover, the close association between HSV-1 and 
Alzheimer’s disease has been gradually recognized 
[16], although the underlying mechanism remains 
obscure. A comprehensive investigation of the 
microglial immune response against HSV-1 infection 
would be beneficial for understanding the brain 
pathogenesis induced by HSV-1 infection. 
Long non-coding RNAs (lncRNAs) are gradually 
recognized as significant components of the innate 
antiviral response [17-19], but functional lncRNAs in 
the microglial innate antiviral response remain 
unknown. Indeed, due to the lack of a translation 
process, non-coding transcripts would be more 
efficient for regulating the response to stress such as 
virus infection, which requires a rapid turn-over. In 
particular, lncRNAs participate in the regulation of 
numerous PTMs [19]. Moreover, although most 
lncRNAs are not conserved, a few lncRNAs have been 
found to harbour conserved fragments [20-22]. 
Besides, we cannot ignore the side effects generated 
by full-length lncRNAs in vivo. We report a novel 
AhR-activated long intergenic non-coding RNA, 
linc-AhRA, which negatively regulates the microglial 
innate antiviral response. linc-AhRA serves as a 
molecular scaffold to enhance TRIM27-TBK1 
interactions via its conserved 117nt fragment at the 
late phase of the antiviral response. This interaction 
facilitates TRIM27-mediated ubiquitination of TBK1 
and leads to TBK1 degradation. As a result, 
linc-AhRA suppresses I-IFNs production and limits 
the microglial innate immune response against 
neurotropic HSV-1 infection, which HSV-1 exploits 
for immune escape. This study provides new insights 
into the regulation mechanism in the microglial I-IFN 
response against neurotropic herpesvirus infection. 
Results 
linc-AhRA is associated with neurotropic 
herpesvirus infection and innate antiviral 
response in microglia 
We first performed the dynamic analysis of IFN 
mRNA expression in microglia upon neurotropic 
herpes simplex virus type 1 (HSV-1) infection at 
different hours post-infection (h.p.i). We found that 
I-IFNs appeared to decrease in the late stage of HSV-1 
infection (Figure S1A). To investigate whether 
lncRNAs were involved in this process, we performed 
high-throughput RNA sequencing of primary 
microglia infected with or without HSV-1 and 
obtained differentially expressed lncRNAs (DELs) 
(Figure 1A and Figure S1B). The upregulated DELs 
were ranked according to their fragments per 
kilo-base of exons per million fragments (FPKM) in 
the steady-state and their fold change induced by 
HSV-1, i.e., FPKMHSV-1/FPKMCells (Table S1 and 
Figure 1B). Only four upregulated DELs ranked in the 
top 15 in both contexts, namely LNC002885, 
LNC000350, ENSMUST00000227851.1 (linc-AhRA), 
and LNC002045 (Figure 1B). ENSMUST00000227851.1 
is an aryl hydrocarbon receptor (AhR) activated-long 
intergenic non-coding RNA (lincRNA) and hereafter 





referred to it as linc-AhRA. linc-AhRA attracted our 
attention for the following reasons: (1) Among those 
four lncRNAs, linc-AhRA is the most abundant 
lncRNA in microglia-like BV2 cells (Figure 1C) and 
primary microglia (Figure 1D and Figure S1C); (2) 
BV2 cells have a higher abundance of linc-AhRA than 
neuron-like Neuro-2a, MEF, and L929 cells (Figure 
1E); (3) An enrichment of linc-AhRA was observed in 
CNS tissues, including in the brain stem (BS), cerebral 
cortex, pons, medulla, and cerebellum (P/M/C), and 
olfactory bulb (OB) (Figure 1F). We performed 5’ and 
3’ rapid amplification of complementary DNA ends 
(RACE) assays to determine the full length of 
linc-AhRA in primary microglia (Figure 1G). We 
found that linc-AhRA contains 682nt without a 
poly-adenylated (poly-A) tail (Table S2). Both the 
coverage tracks from the RNA-seq and Ensemble 
annotation indicated that the gene locus of linc-AhRA 
was located on chromosome 15, nucleotides 25, 414, 
192-25, 414, 873 that linc-AhRA did not overlap with 
known protein-coding genes (Figure S1D-E). Our 
subsequent screen assay indicated that linc-AhRA 
significantly decreased the mRNA level for the I-IFNs, 
Ifnb1 and Ifna4, and the protein level for IFN-β, in 
response to HSV-1 infection (Figure 1H-I) and 
facilitated EGFP-HSV-1 infection in microglia-like 
BV2 cells (Figure 1J). Overexpression of linc-AhRA 
also led to an upregulation of virus titer (Figure S1F). 
 
 
Figure 1. linc-AhRA was identified as a lncRNA involved in the innate antiviral response in microglia upon neurotropic herpesvirus infection. A, Schematic illustration of 
lncRNA-sequencing workflow for total RNA samples from primary microglia with or without HSV-1 infection (multiplicity of infection (MOI) 1). B, Left: Scatter plot for all upregulated DELs 
presenting their FPKM values in cells and the fold change induced by HSV-1 (novel lncRNA with the prefix LNC and annotated lncRNA with the prefix ENSMUST). Right: Venn diagram analysis 





of the overlapped DELs ranking in the top 15 in both basic abundance and fold change upon HSV-1 infection. C, qPCR analysis of the expression of the indicated lncRNAs in BV2 cells. D, Left: 
qPCR analysis of the expression of the indicated lncRNAs in primary microglia. Right: Fluorescence microscopy images of primary microglia to determine the purification of microglia by 
staining IBA-1 (green). Scale bar, 100 μm. E, qPCR analysis of linc-AhRA expression in the indicated cell lines. F, qPCR analysis of linc-AhRA expression in mice tissues (normalized relative to 
the liver) (left). Only the statically comparison result between BS and other non-CNS tissues was labelled. A representative mouse brain with a label of respective region was also provided 
(right). G, 5’RACE and 3’RACE results for RNA from primary microglia infected with HSV-1 for 12 h to obtain the 5’ and 3’ end sequences of linc-AhRA. The normalized gene expressions 
were present. H, qPCR analysis of Ifnα4 and Ifnb1 mRNA levels in BV2 cells transfected with plasmids expressing the indicated lncRNAs for 48 h followed by HSV-1 infection (MOI 1) for 6 
h (empty vector, E.V.). I, ELISA of IFN-β in the supernatants of BV2 cells transfected with plasmids expressing the indicated lncRNAs for 48 h followed by HSV-1 infection (MOI 1) for 12 h. 
J, Left: Fluorescence microscopy images of viral replication (green) in BV2 cells infected with EGFP-HSV-1 (MOI 1) for 24 h, following a transfection of plasmids expressing the indicated 
lncRNAs for 48 h. Scale bar, 500 μm. Right: The quantitative result for relative EGFP fluorescence intensity obtained from three independent experiments. Data are representative of three 
independent experiments (G, J), three independent experiments with n = 3 technical replicates (C-E, H-I), the average of three technical replicates as a mixture (B), each symbol represents 
an individual technical replicate or a mouse (C-F, H-I) or one independent experiment (J) (shown as mean and s.d. in C-F, H-I), two-tailed unpaired Student’s t-test (C-E, H-J). 
 
Next, we tested whether linc-AhRA acts as 
non-coding RNA in the innate antiviral response. 
Bioinformatics analysis using the Coding Potential 
Calculator showed that linc-AhRA lacks coding 
potential [23] (Figure S2A), with a PhyloCSF score < 0 
according to UCSC Genome Browser analysis (Figure 
S2B). However, the NCBI Open Reading Frame (ORF) 
Finder showed three ORFs with more than 70 amino 
acids in linc-AhRA (Figure S2C). To investigate 
whether these ORFs of linc-AhRA can stably translate 
to peptides, we generated several plasmids encoding 
the ORFs fused with an enhanced green fluorescent 
protein (EGFP) at their N terminus. The immuno-
blotting results indicated that EGFP-fused ORF1 and 
ORF4 can generate EGFP-tagged peptides in HEK 
293T cells, but not EGFP-fused ORF3 or the full-length 
linc-AhRA (Figure S2D). However, neither of these 
ORF-coding small peptides reduced the expression of 
Ifnb1 and Ifna4 upon HSV-1 infection (Figure S2E). 
Consistently, only the full length of linc-AhRA, but 
not these ORF-coding small peptides, can result in an 
increment of HSV-1 titer (Figure S2F). Indeed, 
linc-AhRA was cloned into the plasmids using 
frameshift mutation, given its non-coding ability. 
These results indicated that the function of linc-AhRA 
in the innate antiviral response in microglia is not due 
to its encoding small peptides. 
We next explored the association between 
linc-AhRA and virus infection in microglia. linc- 
AhRA exhibited a virus dose-dependent upregulation 
in response to HSV-1 (Figure 2A). linc-AhRA could 
also be induced by numerous innate stimuli, 
including cyclic guanosine monophosphate- 
adenosine monophosphate (cGAMP, a stimulator of 
interferon gene (STING) ligand), toll-like receptor 4 
(TLR4) ligand lipopolysaccharide (LPS), TLR3 ligand 
poly (I: C), 5’ppp-dsRNA, and calf thymus DNA 
(CT-DNA) (Figure 2B). Consistently, RNA blotting 
assays indicated that linc-AhRA was remarkably 
upregulated in BV2 cells in response to 5’ppp-dsRNA 
stimulation and HSV-1 infection (Figure 2C). 
Absolute copy number analysis revealed that 
linc-AhRA was expressed at relatively low levels with 
~25 transcript copies per microglia, which increased 
to ~174 copies per cell upon HSV-1 infection (Figure 
2D), with an abundance similar to that of other 
functional lncRNAs [24]. We next established the 
herpes simplex encephalitis (HSE) mice model. The 
microglia acutely isolated from the HSE mice had a 
higher abundance of linc-AhRA than those from 
normal mice (microglia purification: 96.5%) (Figure 
2E). However, linc-AhRA did not upregulate 
significantly in astrocytes and neurons isolated from 
HSE mice (Figure 2F). The level of linc-AhRA in the 
cerebral cortex tissue from HSE mice was upregulated 
minorly compared to those from normal mice (Figure 
2G). Interestingly, the qRT-PCR results for the 
subcellular fraction of RNAs indicated that linc-AhRA 
was mainly localized in the nucleus in resting 
microglia and that HSV-1 infection led to an 
increment of linc-AhRA in the cytoplasm (Figure 2H). 
Similarly, the RNA fluorescence in situ hybridization 
(FISH) assay demonstrated that HSV-1 infection 
increased linc-AhRA puncta and enhanced the 
nuclear export of linc-AhRA at the late phase of 
infection (Figure 2I). Together, linc-AhRA was 
significantly upregulated and translocated to the 
cytoplasm from the nucleus of the microglia in the late 
stage of neurotropic herpesvirus infection. 
linc-AhRA is mainly regulated by AhR, which is 
activated by HSV-1 infection 
To elucidate the transcription factors (TFs) that 
regulate the expression of linc-AhRA, we predicted 
the TFs by using JASPAR to analyze the linc-AhRA 
promoter (-2,000 bps upstream of the transcription 
start site) [25]. The potential TFs included AhR, 
AT-rich interacting domain-containing 3B (ARID3B), 
androgen receptor (AR), and ARID3A, while AhR had 
the highest probability score (Table S3). There were 
three AhR binding sites within the promoter of 
linc-AhRA. Next, we used validated small interfering 
RNAs (siRNAs) to knock down these TFs and found 
that only knockdown of AhR significantly reduced 
the upregulation of linc-AhRA upon HSV-1 infection 
(Figure 3A). Consistently, pre-treatment with the AhR 
inhibitor CH-223191, but not the AR inhibitor 
ODM-201, significantly suppressed the upregulation 
of linc-AhRA induced by HSV-1 infection (Figure 3B). 
Furthermore, treatment with an AhR agonist such as 
indirubin (Figure 3C) and L-kynurenine (Figure S3A) 
induced the expression of linc-AhRA, and other AhR 
targeted genes, such as Cyp1b1 (encoding cytochrome 
P4501B1) and 2,3,7,8-tetrachlorodibenzo-p-dioxin 





(TCDD)-inducible poly (ADP-ribose) polymerase 
(Tiparp) in a dose-dependent manner. Cyp1b1 and 
Tiparp were also induced by HSV-1 infection in vitro 
(Figure 3D) and in vivo (Figure S3B). The 
overexpression of AhR remarkably stimulated the 
expression of linc-AhRA (Figure 3E). Immuno-
fluorescence results further demonstrated that HSV-1 
infection facilitated the nuclear import of AhRs, more 
evident in the late stage of infection (Figure 3F). We 
next generated AhR-deficient cells using CRISPR- 
Cas9 and found that AhR knockout significantly 
reduced the upregulation of linc-AhRA induced by 
HSV-1 infection (Figure 3G). Indeed, the published 
single-cell RNA sequence data indicated that 
microglia highly express Ahr compared to other cell 
types in the mouse CNS (Figure S3C)[26], suggesting 
the involvement of AhR in the expression of 
linc-AhRA in microglia. An AhR-binding positive 
peak could also be observed in the linc-AhRA 
promoter as showed by the chromatin immuno-
precipitation (ChIP) data for LPS-stimulated mouse 
macrophages as a present by the Cistrome Data 
Browser [27] (Figure S3D). Next, we cloned the 
original and AhR binding-site mutant linc-AhRA 
promoter into pGL4.11[luc2CP] to obtain a 
linc-AhRA-promoter-reporter luciferase and an AhR 
binding-site mutant promoter (Figure 3H). The 
dual-luciferase assay indicated that HSV-1 infection 
enhanced the linc-AhRA promoter activity, which 
was suppressed by the AhR inhibitor CH-223191 
(Figure 3I). However, this behaviour was lost in 
linc-AhRA-promoter with the AhR-binding sites 
mutant (Figure 3I). Treatment with indirubin 
significantly activated the linc-AhRA promoter in a 
dose-dependent manner, which was also lost in the 
promoter with the AhR-binding sites mutant (Figure 
3J). Furthermore, cleavage under targets and 
tagmentation (CUT&Tag) (Figure S4) performed on 
the primary microglia isolated from HSV-1 infected 
mice brain further confirmed that AhR binds to the 
promoter of linc-AhRA in vivo (Figure 3K). The titer of 
the progeny virus from HSV-1-infected AhR-deficient 
BV2 cells was lower than that from WT cells (Figure 
3L). 
linc-AhRA negatively regulates the innate 
antiviral response of microglia 
We next investigated the effect of linc-AhRA on 
the innate antiviral response in BV2 cells and primary 
microglia, using expression plasmids and a lentiviral 
vector of linc-AhRA. We observed a significant 
reduction in the I-IFN Ifnα4 and Ifnb1 mRNAs in 
HSV-1-infected primary microglia with linc-AhRA 
overexpression at different times post-infection 
(Figure S5A). We also found that linc-AhRA 
significantly reduced the mRNA level of Ifnα4, Ifnb1, 
and Cxcl10 during HSV-1 infection in BV2 cells 
(Figure 4A). Also, overexpression of linc-AhRA in 
BV2 cells led to a reduced level of the inflammatory 
factors including Il-6 and Tnf by HSV-1 infection 
(Figure S5B). Next, linc-AhRA was stably 
overexpressed in BV2 cells through lentiviral 
infection. The BV2 cells stably expressing linc-AhRA 
in the context of HSV-1 infection showed a reduced 
level of I-IFN and ISG mRNAs (Figure 4B). The RNA 
sequencing data also suggested that the FPKM value 
of the I-IFNs and several ISGs were significantly 
reduced in HSV-1-infected BV2 cells with a stable 
expression of linc-AhRA (Figure S5C). Overex-
pression of linc-AhRA resulted in a remarkable 
reduction in IFN-β production upon HSV-1 infection 
as indicated by the enzyme-linked immunosorbent 
assay (ELISA) results (Figure 4C). Moreover, 
dual-luciferase assays indicated that linc-AhRA 
suppressed the HSV-1-mediated activation of 
IFN-β-stimulated interferon-stimulated response 
element (ISRE) luciferase activity but not the 
IFN-β-activated ISRE luciferase activity (Figure S5D), 
suggesting linc-AhRA only affected the expression of 
I-IFN but not its downstream signalling transduction. 
Consequently, linc-AhRA overexpression facilitated 
HSV-1 replication in BV2 cells at different times 
post-infection, as supported by HSV-1 genomic DNA 
copy quantification (Figure 4D) and the viral titer 
(Figure 4E). To rigorously examine the role of 
linc-AhRA in the innate antiviral response, we used 
antisense locked nucleic acid (LNA) GapmeRs against 
linc-AhRA. Endogenous linc-AhRA expression was 
successfully reduced by LNA GapmeRs No.466 and 
No.467 (Figure 4F). The knockdown of linc-AhRA by 
antisense LNA GapmeRs in BV2 cells resulted in a 
remarkable increment of I-IFN Ifnα4, Ifnb1, and Cxc10 
expression induced by HSV-1 infection, as compared 
to the LNA GapmeRs negative control group (Figure 
4G). The ELISA result indicated that the knockdown 
of linc-AhRA facilitated the production of IFN-β 
(Figure 4H). Moreover, the knockdown of linc-AhR 
by LNA GapmeRs significantly reduced the HSV-1 
titer (Figure 4I). EGFP-HSV-1 infection in BV2 cells 
with linc-AhRA knockdown showed reduced 
fluorescence intensity (Figure 4J). Two LNA 
GapmeRs yielded similar results, demonstrating that 
the effect was highly unlikely to have been produced 
by a nonspecific LNA-dependent mechanism. 
However, overexpression of linc-AhRA in 
Neuro-2a cells failed to affect the innate antiviral 
response upon HSV-1 infection (Figure S6A). 
Additionally, linc-AhRA showed no effect on viral 
genomic DNA copies (Figure S6B) and EGFP 
intensity (Figure S6C) in EGFP-HSV-1-infected 





Neuro-2a cells. Together, these results indicate that 
linc-AhRA mainly functions in the innate antiviral 
response in microglia but not in neurons. Given that 
microglial I-IFNs bestow antiviral capabilities to 
neurons, we next tested the effect of microglial 
linc-AhRA on the antiviral activity of neuron-like 
Neuro-2a cells against HSV-1 infection using 
microglia conditioned medium (MCM) (Figure S6D) 
Pre-treatment with MCM from CT-DNA-stimulated 
BV2 cells that stably expressed linc-AhRA led to a 
remarkable increase of the HSV-1 load in Neuro-2a 
cells (Figure S6E). By contrast, pre-treatment with 
MCM from CT-DNA-stimulated BV2 cells with LNAs 
targeting linc-AhRA conferred stronger antiviral 
activity to Neuro-2a cells than that from cells with 
control LNA (Figure S6F). 
 
 
Figure 2. linc-AhRA is upregulated in response to numerous innate stimuli and relocated into the cytosol upon HSV-1 infection. A, qPCR analysis of linc-AhRA level 
following a 12 h infection with HSV-1 in BV2 cells with MOI as labeled. The “normalized gene expression” was abbreviated into “norm. gene exp.”. B, qPCR analysis of linc-AhRA level in BV2 
cells with the indicated stimulation for 6 h (3'-3'-cGAMP, 5’ppp-dsRNA, and CT-DNA, 1 μg/ml; LPS, 100 ng/ml). C, Northern blotting analysis for RNA from BV2 cells with or without HSV-1 
(MOI 1) or 5’ppp-dsRNA stimulation (1 μg/ml) for 12 h. D, Copy-number analysis of linc-AhRA in BV2 cells infected with HSV-1 (MOI 1) for 9 h using qPCR. E, Left: Flow cytometry analysis 
of microglia following acute isolation from mice using CD11b-coupled magnetic beads. The ratio of the CD11b+ subset is also presented. Right: qPCR analysis of linc-AhRA level in microglia 
acutely isolated from normal and HSE mice at 9 d.p.i. F, qPCR analysis of linc-AhRA level in primary astrocyte (left) and neuron (right) isolated from normal and HSE mice at 9 d.p.i. G, qPCR 
analysis of linc-AhRA level in cerebral cortex from normal and HSE mice at 9 d.p.i. H, qPCR analysis of cytoplasmic and nuclear ratios of linc-AhRA, Neat1, and 18s in BV2 cells after HSV-1 
infection for 24 h. I, Top: RNA FISH showing linc-AhRA (yellow) in BV2 with HSV-1 (MOI 1) infection for 24 h. The nuclei were stained with DAPI (cyan). Scale bar, 10 μm. Bottom: The 
relative fluorescence intensity of linc-AhRA in the cytoplasm and nucleus from three random regions was determined using the ImageJ program. Data are representative of three independent 
experiments (C, I[top]), three independent experiments with n =3 technical replicates (A-B, D-E[right], F, H-I) or with n = 4 individuals (G), each symbol represents an individual or 
technical replicate or one region (A-B, D-E[right], F-I[bottom]) (shown as mean and s.d. in A-B, D-E[right], F-I[bottom]), two-tailed unpaired Student’s t-test (B, D-E[right], 
F-I[bottom]), One-way ANOVA (and nonparametric analysis) (A). 






Figure 3. The induction of linc-AhRA by HSV-1 infection is mainly mediated by AhR signaling. A, qPCR analysis of linc-AhRA expression in BV2 cells 48 h after transfecting the 
indicated siRNA and HSV-1 infection (MOI 1) for 9 h. B, qPCR analysis of the expression of the indicated genes in BV2 cells infected with HSV-1 (MOI 1) for 12 h in the presence of CH-223191 
(50 nM) and ODM-201 (100 nM). C, qPCR analysis of the expression of the indicated genes in BV2 cells 9 h after stimulation with indirubin with the indicated concentration. D, qPCR analysis 
of the expression of the indicated genes in BV2 cells with HSV-1 infection (MOI 1) for 12 h. E, Left: qPCR analysis of linc-AhRA expression in BV2 cells 48 h after the transfection of 
AhR-expressing plasmids; right: Immunoblot analysis of AhR level in BV2 cells 48 h after the transfection of AhR-expressing plasmids. F, Confocal microscope-based fluorescence analysis of 
the nuclear localization of AhR (green) in BV2 cells with HSV-1 infection (MOI 1) for the indicated hours. Nuclei were labeled with DAPI (blue). Scale bars, 10 μm. G, Top: qPCR analysis of 
linc-AhRA expression in gRNA-based AhR-deficient or control BV2 cells with HSV-1 infection (MOI 1) for 9 h; bottom: Immunoblot analysis of AhR level in gRNA-based AhR-deficient or 
control BV2 cells with HSV-1 infection (MOI 1) for 9 h. H, Left (top): The sequence logo recognized and bound by AhR; left (bottom): Schematic illustration for the construction of a firefly 
luciferase reporter driven by the primitive promoter or AhR binding site (BS) mutant promoter of linc-AhRA; right: The Sanger sequencing peak for the AhR-binding site mutant and primitive 
promoter-driven luciferase plasmids. I, Dual luciferase analysis of linc-AhRA primitive and AhR-binding site mutant promoter activity in BV2 cells 24 h after co-transfection of a firefly luciferase 
reporter (linc-AhRA pro.-luc) and TK-renilla, followed by HSV-1 infection (MOI 1) for another 12 h. J, Dual luciferase analysis of linc-AhRA primitive and AhR-binding site mutant promoter 
activity in BV2 cells 24 h after co-transfection of a linc-AhRA pro.-luc and TK-renilla, followed by the treatment of indirubin at the indicated concentration for another 6 h. K, Determination 
of HSV-1 titers in culture medium supernatants of gRNA-based AhR-deficient or control BV2 cells with HSV-1 infection (MOI 1) for the indicated number of hours using a plaque formation 
assay. L, AhR CUT&Tag-qPCR analysis of the enrichment of the fragment containing AhR binding sites within the linc-AhRA promoter using two primer sets for microglia acutely isolated from 
C57BL/6J mice with HSV-1 infection for 9 days. Data are representative of three independent experiments with n = 3 technical replicates (A-E[left], G[top], I-L) or n = 3 mice (K), three 
independent experiments (E[right]-G[bottom]), each symbol represents an individual or technical replicate(A-E[left], G[top], I-J) or an individual mouse (K) (shown as mean and s.d. 
in A-D, E[right], G[top], I-L), two-tailed unpaired Student’s t-test (A-B, D-E, G[top], K), One-way ANOVA (and nonparametric analysis) (C, I-J), two-way ANOVA (L). 






Figure 4. linc-AhRA negatively regulates microglial innate antiviral response. A, qPCR analysis of the expression of the indicated genes in BV2 cells transfected with 
linc-AhRA-expressing and E.V. plasmids, followed 48 h later by HSV-1 infection (MOI 1) for 12 h. B, qPCR analysis of the expression of the indicated genes in BV2 cells stably expressing 
linc-AhRA, followed by HSV-1 infection (MOI 1) for 12 h. C, ELISA of IFN-β in the supernatants of BV2 cells stably expressing linc-AhRA, followed by HSV-1 infection (MOI 1) for the indicated 
hours. D, Determination of viral DNA copies in BV2 cells stably expressing linc-AhRA with HSV-1 infection (MOI 1) for 24 h using qPCR. E, Determination of HSV-1 titers in culture medium 
supernatants of BV2 cells stably expressing linc-AhRA with HSV-1 infection (MOI 1) for the indicated duration using a plaque formation assay. F, qPCR analysis of the expression of linc-AhRA 
in BV2 cells transfected with LNA targeting linc-AhRA at different sites (LNA-466, LNA-467, and LNA-469) or control LNA for 24 h. G, qPCR analysis of the expression of the indicated genes 
in BV2 cells transfected with LNA targeting linc-AhRA at different sites (LNA-466 and LNA-467) or control LNA, followed 24 h later by HSV-1 infection (MOI 1) for 12 h. H, ELISA of IFN-β 
in the supernatants of BV2 cells transfected with LNA targeting linc-AhRA at different sites (LNA-466 and LNA-467) or control LNA, followed 24 h later by HSV-1 infection (MOI 1) for the 
indicated duration. I, Determination of HSV-1 titers in culture medium supernatants of BV2 cells transfected with LNA targeting linc-AhRA at different sites (LNA-466 and LNA-467) or 
control LNA, followed 24 h later by HSV-1 infection (MOI 1) for the indicated duration using a plaque formation assay. J, Left, Fluorescence microscopy images of viral replication (green) in 
BV2 cells with EGFP-HSV-1 (MOI 1) infection for 24 h, following the transfection of LNA targeting linc-AhRA (LNA-466 and LNA-467) or control LNA for 24 h. Scale bar, 100 μm. right, The 
quantitative result for relative EGFP fluorescence intensity obtained from three independent experiments. Data are representative of three independent experiments with n = 3 technical 
replicates (A-I), three independent experiments (J), each symbol represents an individual technical replicate (A-D, F-G) or one independent experiment (J[right]) (shown as mean and s.d. 
in A-J[right]), two-tailed unpaired Student’s t-test (A-B, D, F-G, J[right]), two-way ANOVA (C, E, H-I). 
 
linc-AhRA facilitates the degradation of TBK1 
in a proteasome-dependent manner, resulting 
in the suppression of I-IFN production 
Next, to investigate the mechanism of action of 
linc-AhRA in the modulation of the innate antiviral 
response, we examined the effect of linc-AhRA on 
viral entry and the amount of cyclic GMP-AMP 
synthase (cGAS)-binding viral DNA, which the 
cGAS-STING pathway uses to detect cytosolic DNA 
and induce an immune response. The flow cytometry 
results for reporter virus EGFP-HSV-1 and qPCR for 
viral DNA indicated that linc-AhRA did not reduce 
the viral entry amount (Figure S7A-B). Further, qPCR 
analysis for viral DNA isolated from cGAS 
immunoprecipitation demonstrated that the amount 
of DNA binding by cGAS was not affected by 
linc-AhRA (Figure S7C-D). Collectively, the 
inhibition of I-IFNs by linc-AhRA was not due to a 
reduction in the amount of the intracellular virus or 
cGAS-binding viral DNA. We next examined the level 
of linc-AhRA involvement in the molecular order of 
PRR-triggered signalling using co-transfected 
plasmids expressing the innate signalling components 
together with Ifnb1 promoter-reporter plasmids. We 
found that the activation of Ifnb1 promoter by 
cGAS+STING, mitochondrial antiviral signalling 
protein (MAVS), and TBK1 was significantly 





suppressed by linc-AhRA (Figure 5A). In contrast, 
linc-AhRA did not affect the constitutively active 
mutant IRF3(D)-mediated activation of Ifnb1 promoter 
activity (Figure 5A). Consistently, linc-AhRA only 
reduced the induction of Ifnb1 expression by 
cGAS+STING, MAVS, or TBK1, but not the 
constitutively active mutant IRF3(D) (Figure 5B). 
Indeed, the induction of Ifnb1 in response to 
stimulation with CT-DNA and 5'ppp-dsRNA was also 
suppressed by linc-AhRA overexpression (Figure 
S8A), suggesting that linc-AhRA may regulate the 
cross-point of innate antiviral response against DNA 
and RNA virus. Moreover, the immunoblotting 
results suggested that the phosphorylation of IRF3 
and TBK1 triggered by HSV-1 infection was 
attenuated in BV2 cells with stable expression of 
linc-AhRA (Figure 5C). Of note, a lower level of TBK1 
protein was observed in BV2 cells with stable 
expression of linc-AhRA compared to the level in 
control cells, but did not significantly alter other 
factors except for cGAS (Figure 5C). Similar results 
were also observed in primary microglia (Figure 
S8B). These results suggest that linc-AhRA might 
limit I-IFN production through targeting TBK1. 
 
 
Figure 5. linc-AhRA facilitates TBK1 degradation in a proteasome-dependent manner. A, Dual luciferase analysis of IFN-β promoter activity in HEK 293T cells 36 h after 
co-transfecting linc-AhRA expressing plasmids (or E.V.), a firefly luciferase reporter (IFN-β-Luc), and TK-renilla with the indicated plasmids encoding cGAS and STING, TBK1, MAVS, and 





IRF3(D). B, qPCR analysis of Ifnb1 expression in BV2 cells stably expressing linc-AhRA 36 h after transfection with the indicated plasmids encoding cGAS and STING, TBK1, MAVS, or IRF3(D). 
C, Immunoblot analysis of cGAS-STING signaling pathways in BV2 cells stably expressing linc-AhRA and control cells infected with HSV-1 (MOI 1) for the indicated hours. D, qPCR analysis 
of the expression of the indicated genes in BV2 cells stably expressing linc-AhRA and the corresponding control cells. E, qPCR analysis of the cytoplasmic and nuclear Tbk1 level in BV2 cells 
stably expressing linc-AhRA. F, Immunoblot analysis of TBK1 level in BV2 cells transfected with linc-AhRA transcripts (2 μg) and antisense transcripts (2 μg) for the indicated number of hours, 
following pretreatment with CHX (10 μg/ml) for 6 h. G, Immunoblot analysis of HA in HEK 293T cells co-transfected with an equal amount of HA-fusion indicated factors expressing plasmids 
and pEGFP-C1 plasmids for 48 h. EGFP was present as a control for the transfection efficiency. H, Immunoblot analysis of cGAS-STING signaling pathways in BV2 cells with HSV-1 infection 
(MOI 1) for 24 h, following a transfection of the LNA control or LNA targeting linc-AhRA at different sites for 24 h. I, Immunoblot analysis of TBK1 level in BV2 cells with indirubin (50 μM) 
treatment for 9 h. J, Immunoblot analysis of TBK1 level in BV2 cells stably expressing linc-AhRA and treated with 3-MA (5 mM) and MG-132 (10 μM) for the indicated hours. K, qPCR analysis 
of Ifnb1 and Ifnα4 expression in BV2 cells stably expressing linc-AhRA or control cells treated with 3-MA (5 mM) and MG-132 (10 μM) in the context of HSV-1 (MOI 1) infection for 6 h. Data 
are normalized relative to the control group with the treatment of DMSO. L, Dual luciferase analysis of IFN-β promoter activity in control and linc-AhRA stably expressing BV2 cells 30 h after 
co-transfecting a firefly luciferase reporter (IFN-β-Luc) and TK-renilla, followed by treatment with 3-MA (5 mM) or MG-132 (10 μM) in the context of HSV-1 infection (MOI 1) for another 
6 h. M, Determination of HSV-1 titers in culture medium supernatants of BV2 cells stably expressing linc-AhRA with HSV-1 infection (MOI 1) for 12 h in the presence of MG-132 (10 μM) for 
first 6 h. Data are representative of three independent experiments (C, F, G-J), three independent experiments with n = 3 technical replicates (A-B, D-E, K-M), each symbol represents an 
individual technical replicate (A-B, D-E, K-M) (shown as mean and s.d. in A-B, D-E, K-M), two-tailed unpaired Student’s t-test (A-B, D-E, K-M). 
 
To determine how linc-AhRA acts at the TBK1 
level, we first investigated the effects of linc-AhRA on 
Tbk1 mRNA expression. The results demonstrated 
that linc-AhRA had a minor effect on the expression 
of Tbk1 (Figure 5D). However, treatment with 
recombinant IFN-β largely restored the reduction of 
Tbk1 mRNA induced by linc-AhRA (Figure S8C), 
implying that the effect of linc-AhRA on Tbk1 mRNA 
may have resulted from the reduction of IFN-β. 
Nucleocytoplasmic trafficking is also an emerging 
manner for the modulation of targeted proteins [28]. 
However, linc-AhRA did not disrupt the 
nucleocytoplasmic trafficking of Tbk1 mRNA (Figure 
5E). Together, there may be other mechanisms for 
TBK1 regulation by linc-AhRA. Interestingly, upon 
chlorhexidine (CHX) treatment to inhibit de novo 
protein synthesis, linc-AhRA transcripts obtained 
from in vitro transcription facilitated the degradation 
of TBK1 (Figure 5F), thereby supporting the 
regulatory role of linc-AhRA in TBK1 stability. 
Overexpression of linc-AhRA also reduced TBK1 
expression from plasmids, with little effect on other 
IFN signaling factors, including cGAS, IRF3, and 
MAVS (Figure 5G). Of note, knockdown of 
linc-AhRA with LNA GapmeRs increased the protein 
level of TBK1 but had a minor effect on other factors 
(Figure 5H). Treatment with the AhR agonist 
indirubin also induced the degradation of TBK1 in 
BV2 cells (Figure 5I). We next used the autophagy 
inhibitor 3-MA and proteasome inhibitor MG-132 to 
elucidate the pathway of TBK1 degradation induced 
by linc-AhRA. MG-132, but not 3-MA, blocked the 
loss of TBK1 protein induced by linc-AhRA 
overexpression (Figure 5J). Treatment with MG-132 
also restored the linc-AhRA-mediated reduction of 
Ifnb1 and Ifnα4 mRNA expression (Figure 5K) and the 
impairment of Ifnb1 promoter activity induced by 
HSV-1 infection (Figure 5L). Further, MG-132 
treatment abolished the inhibition effect of linc-AhRA 
overexpression on HSV-1 replication (Figure 5M). 
Collectively, proteasome, but not autophagy, is 
involved in TBK1 degradation mediated by 
linc-AhRA. 
A reduced level of TBK1 protein was also 
observed at the late phase of HSV-1 infection when 
linc-AhRA was significantly upregulated (Figure 6A). 
A degradation of TBK1 was observed in HMC3 cells 
in the late stage of HSV-1 infection (Figure 6B). 
Moreover, the knockdown of linc-AhRA restored the 
HSV-1-enhanced ubiquitination and degradation of 
TBK1 (Figure 6C-D). Indeed, overexpression of 
linc-AhRA is sufficient to increase the ubiquitination 
of TBK1 in the absence of HSV-1 infection (Figure 6E). 
These results indicated that the accumulation of 
linc-AhRA leads to a degradation of TBK1 at the late 
stage of HSV-1 infection in microglia. 
linc-AhRA acts as a scaffold and enhances 
TRIM27-TBK1 interaction 
Next, we attempted to determine how 
linc-AhRA induces the degradation of TBK1 and first 
tested the possibility that linc-AhRA modulated the 
expression of its neighbour genes. The brain 
acid-soluble protein 1 (Basp1) was identified as the 
only neighbour coding gene with a distance of less 
than 100,000 bps. However, overexpression of 
linc-AhRA did not affect the mRNA expression of 
Basp1 in BV2 cells with or without HSV-1 infection 
(Figure S9A-B). Therefore, it is unlikely that 
linc-AhRA functions by regulating the expression of 
BASP1. Indeed, linc-AhRA still led to the degradation 
of TBK1 after blocking protein synthesis (above), 
suggesting the degradation of TBK1 may not be 
caused by the downstream genes of linc-AhRA. 
Therefore, we next focused on whether linc-AhRA 
interacts with TBK1. Given the addition of the tRNA 
scaffold to a streptavidin aptamer (tRSA) increased 
binding efficiency by ∼10-fold [29], tRSA-linc-AhRA 
or tRSA transcripts were incubated with BV2 cell 
lysates, and the enriched protein samples were 
analyzed with an immunoblotting assay (Figure 7A, 
left). The immunoblotting results showed that 
linc-AhRA interacted with TBK1, but not with other 
crucial factors, including MAVS, cGAS, STING, and 
IRF3 (Figure 7A, right). Further, considering that 
linc-AhRA enhanced the ubiquitination of TBK1 
(above), we speculated that linc-AhRA might bind to 
the specific E3 ubiquitin ligase of TBK1. We predicted 
the E3 ubiquitin ligase using Ubibrowser and 
summarized the known E3 ligases of TBK1 





(DEAD-box helicase 19A (DDX19A), Deltex E3 
Ubiquitin Ligase 4 (DTX4), TRAF-interacting protein 
(TRIP), and TRIM27) [10, 11, 13, 30, 31] (Figure 7B). To 
identify the E3 ligases that interact linc-AhRA, the 
specific bands observed in the linc-AhRA pull-down 
enrichment indicated by silver staining were analyzed 
with mass spectrometry (MS) (Figure 7C). Among 
these known and predicted E3 ubiquitin ligases of 
TBK1, only TRIM27 was identified in tRSA-linc-AhRA 
enriched lysates using MS (Figure 7C-D). The result 
was further confirmed by immunoblotting (Figure 
7E). Next, TRIM27-TBK1 interactions were confirmed 
in BV2 cells at the late phase of HSV-1 infection but 
not in the absence of HSV-1 infection (Figure S10A). 
Additionally, confocal microscopy imaging revealed a 
co-localization of TRIM27 and TBK1 in the cytoplasm 
and nuclear export of TRIM27 in the late stage of 
infection (Figure S10B). However, the RNA 
immunoprecipitation (RIP)-qPCR results (Figure 7F) 
indicated that TBK1-linc-AhRA interactions were only 
observed in microglia with HSV-1 infection at the late 
stage, but not in microglia without HSV-1 infection 
(Figure 7G). In contrast, TRIM27 interacted with 
linc-AhRA in an HSV-1-infection-independent 
manner, and HSV-1 infection strengthened the 
linc-AhRA-TRIM27 interaction (Figure 7H). Indeed, a 
time course matched expression profile indicated that 
Trim27 and linc-AhRA upregulated significantly in the 
late phase of HSV-1 infection in primary microglia 
(Figure S10C). By contrast, both of which were not 
upregulated significantly in the neuron in the context 
of HSV-1 infection (Figure S10D). Apoptotic is the 
central manner of cell death during HSV-1 infection 
[32]. The apoptotic Caspases were known to suppress 
I-IFN production in numerous manners [33-35]. We 
next used Z-VAD-FMK, a general Caspase inhibitor, 
to investigate whether the inhibition effect of 
linc-AhRA on I-IFN expression were involved 
Caspase-mediated cell death. The qRT-PCR result 
indicated that the overexpression of linc-AhRA 
induced by HSV-1 or mediated by plasmids still 
reduced Ifnb1 expression in the presence of 
Z-VAD-FMK (Figure S10E-F). Such a result excluded 
the possibility that the decrease in Ifnb1 expression in 
the context of linc-AhRA overexpression or in the late 
phase of HSV-1 infection is due to cell death. 
Moreover, knockdown of 
TRIM27 using validated siRNA 
was sufficient to facilitate the 
expression of I-IFNs and ISGs 
under HSV-1 infection (Figure 
S10G). We next investigated 
whether linc-AhRA binds to 
TBK1 before interacting with 
TRIM27. Notably, the RIP assay 
demonstrated that linc-AhRA 
failed to bind to TBK1 in 
Trim27-knockdown BV2 cells at 
the late stage of HSV-1 infection 
(Figure 7I). Additionally, the 
knockdown of TRIM27 restored 
the linc-AhRA-mediated 
reduction of I-IFN expression 
(Figure 7J) and the degradation 
of TBK1 (Figure 7K). Moreover, 
the results for the fluorescence 
intensity of reporter virus 
EGFP-HSV-1 suggested that 
knockdown of TRIM27 inhibited 
the effect of linc-AhRA on HSV-1 
replication (Figure 7L) and the 
viral DNA copy numbers (Figure 
7M). Collectively, linc-AhRA 
may regulate the innate antiviral 




Figure 6. HSV-1 infection led to a degradation of TBK1 at the late stage of infection, which were partially 
mediated by linc-AhRA. A, Top: Immunoblot analysis of TBK1 level in BV2 cells with HSV-1 infection (MOI 1) for the 
indicated number of hours. Bottom: Band density of TBK1 in the immunoblot result presented on top and qPCR analysis of 
linc-AhRA expression in BV2 cells with HSV-1 infection (MOI 1) for the indicated number of hours. B, Immunoblot analysis of 
TBK1 level in HMC3 cells with HSV-1 infection (MOI 1) for the indicated number of hours. C, Immunoblot analysis of 
ubiquitinated TBK1 level using immunoprecipitation with anti-TBK1 antibody in BV2 cells with LNA-mediated knockdown of 
linc-AhRA followed by HSV-1 infection (MOI 1) for 24 h. D, Immunoblot analysis of TBK1 level in BV2 cells with the same 
treatment as in (C). E, The ubiquitination of TBK1 in linc-AhRA-overexpressing BV2 cells was assessed by immunoprecipitation 
with anti-TBK1 antibody. Data are representative of three independent experiments (A[top]- E), three independent 
experiments with n = 3 technical replicates (E[bottom]) (shown as mean and s.d. in A[bottom]), One-way ANOVA (and 
nonparametric analysis) (A[bottom]). 






Figure 7. linc-AhRA interacts with TRIM27 and HSV-1 infection induces the binding of linc-AhRA to TBK1. A, Left: Schematic illustration of tRSA RNA pull-down assay; 
right: Immunoblot analysis of the indicated factors in tRSA and tRSA-linc-AhRA pull-down enrichment. B, Left: Flower plot of the predicted E3 ligases targeting TBK1, analyzed using 
Ubibrowser; right: List of known E3 ligases of TBK1. C, Left: SDS-PAGE with silver nitrate staining analysis of proteins co-purified with linc-AhRA. The specific bands (label in red) within the 
tRSA-linc-AhRA group were extracted for mass spectrometry (MS) analysis; right: The partial list of proteins identified by MS. D, Venn diagram analysis for the overlapped E3 ligase of TBK1 
both in the list as presented in (B) and in MS-identified factors as in (C). E, Immunoblot analysis of the indicated E3 ligase in tRSA and tRSA-linc-AhRA pull-down enrichment. F, Schematic 
illustration of RNA immunoprecipitation assay. G, Top: Immunoblot analysis of TBK1 immunoprecipitated by TBK1-specific antibody or immunoglobulin G (IgG) from BV2 cells uninfected 
or infected with HSV-1 (MOI 1) for 24 h; bottom: RIP-qPCR analysis of linc-AhRA immunoprecipitated from same samples as in (top). H, Top: Immunoblot analysis of TRIM27 
immunoprecipitated with TRIM27-specific antibody or IgG from BV2 cells with the same treatment as in (G); bottom: RIP-qPCR analysis of linc-AhRA immunoprecipitated from same samples 
as in (H). I, Top: Immunoblot analysis of TBK1 immunoprecipitated with TBK1-specific antibody or IgG from BV2 cells transfected with TRIM27 siRNA for 48 h then infected with HSV-1 
(MOI 1) for 24 h; bottom: RIP-qPCR analysis of linc-AhRA immunoprecipitated by TBK1-specific antibody or IgG from samples as in (top). J, qPCR analysis of the expression of the indicated 
genes in BV2 cells stably expressing linc-AhRA and transfected with TRIM27 siRNA for 48 h then infected with HSV-1 (MOI 1) for 6 h. K, Immunoblot analysis of TBK1 and TRIM27 levels in 
BV2 cells stably expressing linc-AhRA and transfected with TRIM27 siRNA for 48 h. L, Fluorescence microscopy images of HSV-1 (green) replication in BV2 cells co-transfected with 
linc-AhRA and TRIM27 siRNA for 48 h, followed by EGFP-HSV-1 infection (MOI 2) for 24 h. Scale bar, 100 μm. M, Determination of viral DNA copies using qPCR in BV2 cells stably expressing 
linc-AhRA with a transfection of TRIM27 siRNA for 48 h infected with HSV-1 (MOI 2) for 24 h. Data are representative of three independent experiments (A, C, E, G-I[top], K, L), three 
independent experiments with n = 3 technical replicates (G-I[bottom], J, M), each symbol represents an individual technical replicate (G-I[bottom], J, M) (shown as mean and s.d. in 
G-I[bottom], J, M), two-tailed unpaired Student’s t-test (G-I[bottom], J, M). 






Figure 8. linc-AhRA acts as a scaffold enhancing TBK1-TRIM27 interaction to facilitate the TRIM27-mediated degradation of TBK1. A, Co-immunoprecipitation (Co-IP) 
analysis of the TBK1-TRIM27 interactions in HEK 293T cells co-transfected with FLAG-TRIM27, HA-TBK1, and linc-AhRA for 42 h, followed by MG-132 treatment (10 μM) for another 6 h. 
B, Confocal microscope-based fluorescence analysis of the co-localization of TBK1 (green) and TRIM27 (red) in BV2 cells stably expressing linc-AhRA with MG-132 treatment (10 μM) for 6 
h. Nuclei were labeled with DAPI (blue). Scale bars, 10 μm. n = 30 cells per group were subjected to analysis. C, Immunoblot analysis of HA and FLAG level in HEK 293T cells co-transfected 
with FLAG-TRIM27, HA-TBK1, and linc-AhRA for 48 h. D, Co-IP analysis of the TBK1-TRIM27 interaction and TBK1 ubiquitination in BV2 cells transfected with LNA-Ctrl or LNA-466 for 
24 h and infected with HSV-1 (MOI 1) for 24 h. E, Confocal microscope-based fluorescence analysis of the co-localization of endogenous TBK1 (green) and TRIM27 (red) in BV2 cells 
transfected with LNA-Ctrl or LNA-466 for 24 h and infected with HSV-1 (MOI 1) for another 24 h in the presence of MG-132 (10 μM) for the final 6 h. Nuclei were labeled with DAPI (blue). 
Scale bars, 10 μm. n = 30 cells per group were subjected to analysis. F, Heatmap indicating the interaction propensity between linc-AhRA and TRIM27 analyzed by catRAPID expression. G, 
Heatmap indicating the interaction propensity between linc-AhRA and TBK1 analyzed by catRAPID expression. H, RNA pull-down assay of the binding of linc-AhRA to FLAG-tagged 
truncations of TRIM27 using the lysates of HEK 293T cells transfected with the corresponding plasmids as in (B) for 48 h. I, RNA pull-down assay of the binding of linc-AhRA to HA-tagged 
truncations of TBK1 using the lysates of HEK 293T cells transfected with the corresponding plasmids as in (A) for 48 h. Data are representative of three independent experiments (A-E, H-I). 
 
We next investigated the effect of linc-AhRA on 
TBK1-TRIM27 interactions. We found that linc-AhRA 
overexpression strengthened TBK1-TRIM27 interact-
ions (Figure 8A) without affecting the mRNA 
expression and HSV-1 infection-induced nuclear 
export of TRIM27 (Figure S10H-I). In addition, 





linc-AhRA did not affect the protein level of TRIM27 
(above). The confocal images showed that linc-AhRA 
enhanced the co-localization of TBK1 and TRIM27 
(Figure 8B). The TRIM27-mediated degradation of 
TBK1 was further enhanced by linc-AhRA (Figure 
8C). Next, we examined whether HSV-1 infection- 
induced TBK1 degradation was associated with the 
linc-AhRA-mediated enhancement of TBK1-TRIM27 
interaction. Knockdown of linc-AhRA by LNA 
reduced the HSV-1-induced ubiquitination of TBK1 
and TBK1-TRIM27 interactions (Figure 8D). The 
confocal images also demonstrated that knockdown 
of linc-AhRA attenuated the HSV-1-induced 
co-localization of TBK1 with TRIM27 at the late stage 
of infection (Figure 8E). Together, linc-AhRA 
enhanced the TRIM27-TBK1 interaction, thereby 
facilitating the ubiquitination and degradation of 
TBK1. 
To characterize the TBK1-TRIM27 interactions in 
detail, we constructed plasmids expressing an 
HA-tagged domain of TBK1 and a FLAG-tagged 
domain of TRIM27 (Figure S11A-B, top). 
Immunoprecipitation and immunoblot analyses 
showed that TRIM27-TBK1 interactions were 
mediated by their respective coiled-coil domains 
(Figure S11A-B, bottom), which is consistent with a 
previous study [10]. Next, we used catRAPID 
expression to predict the propensity of interaction 
between TBK1 or TRIM27 and linc-AhRA. catRAPID 
expression is a tool for predicting the interaction 
propensity of a protein-RNA pair and reports the 
interaction score and the discriminative power [36, 
37]. The interaction matrix calculated by catRAPID 
expression indicated that TRIM27, as an RNA-binding 
protein (RBP) recently recognized [38], showed an 
excellent propensity for interacting with linc-AhRA in 
general (Figure 8F). In contrast, only the coiled-coil 
domain of TBK1 showed strong interaction 
propensity with linc-AhRA (Figure 8G). We next 
performed tRSA RNA pull-down assays using cell 
lysates containing various truncated fragments of 
TRIM27 or TBK1 to determine the region of 
interaction between TBK1 or TRIM27 and linc-AhRA. 
Partially consistent with the predictions obtained 
from catRAPID graphic, the RNA pull-down assay 
indicated that the binding of TRIM27 to linc-AhRA 
was mediated by the SPla/Ryanodine receptor 
(SPRY) domain of TRIM27 (Figure 8H). In contrast, 
the coiled-coil domain of TBK1 mediated its 
interaction with linc-AhRA (Figure 8I), which is 
entirely consistent with the analysis results from 
catRAPID graphic. 
The conserved 117nt fragment is required for 
the enhancement of TRIM27-TBK1 interaction 
mediated by linc-AhRA 
To determine whether an equivalent lncRNA is 
located in the human genome corresponding to 
mouse linc-AhRA, we performed a conservation 
analysis for linc-AhRA. Although the Placental 
mammal Basewise Conservation track identified by 
PhyloP among 60 vertebrates indicated that 
linc-AhRA is not generally conserved, further analysis 
limited to mice, rats, and humans revealed a 117nt 
(245-361nt) conserved fragment within linc-AhRA 
(Figure 9A and Figure S12A). Based on this conserved 
fragment, we used the RACE assay to obtain an 
equivalent lncRNA named BASP-AS1 located in the 
human genome corresponding to mouse linc-AhRA in 
HMC3 cells (Figure S12B). The results indicated that 
BASP-AS1 is a spliced transcript of 3327nt with a 
poly-A tail (Table S4). Although HSV-1 infection 
stimulated the expression of BASP-AS1 (Figure 
S12C), BASP-AS1 did not affect the microglial innate 
antiviral response or the virus titers in HMC3 cells 
(Figure S12D-E). However, the conserved 117nt 
fragment increased the HSV-1 titers (Figure S12E) 
and suppressed the expression of IFNB1 in the HMC3 
cells (Figure S12F). Moreover, GTEx (release version 
6) indicated that brain tissues had the highest 
abundance of BASP-AS1 among all human tissues 
(Figure S12G), suggesting a potential implication of 
BASP-AS1 in CNS. 
To characterize the region within linc-AhRA that 
interacts with TBK1 and TRIM27 in detail, we used 
catRAPID fragments to calculate the interaction 
propensities of linc-AhRA with TBK1 and TRIM27. 
catRAPID fragments predict RNA-protein interaction 
propensities based on a procedure that involves the 
division of polypeptide and nucleotide sequences into 
fragments. The results showed that a fragment 
(207-377nt) within linc-AhRA had the highest score 
for binding to TRIM27 (Figure 9B) and TBK1 (Figure 
9C) (Table S5 and Table S6). Of note, this region 
contained the 117nt conserved fragments (245-361nt). 
Based on the 117nt conserved fragment, we 
constructed a series of deletion mutant fragments for 
linc-AhRA, specifically Mut 1, Mut 2, Mut 3, Mut 4, 
117nt, and Δ117nt (Figure 9D and Figure S13). We 
found that only the linc-AhRA truncated fragments 
containing the 117nt conserved fragment could 
degrade TBK1 in murine microglia (Figure 9D). 
Further, RNA pull-down analysis revealed that 
linc-AhRA mutants lacking the conserved 117nt 
fragment could no longer bind to TBK1 and TRIM27 
and degrade TBK1 (Figure 9E). Interestingly, both 
linc-AhRA and the 117nt conserved fragment, but not 
BASP-AS1, can degrade TBK1 in human microglia- 





like HMC3 cells (Figure 9F). Further, the linc-AhRA 
mutants lacking the conserved 117nt fragment could 
not inhibit HSV-1-infection-activated IFN-β luciferase, 
whereas linc-AhRA fragments containing the 
conserved 117nt fragment retained this function 
(Figure 9G).  
 
 
Figure 9. The conserved 117nt fragment is required for the enhancement of TRIM27-TBK1 interaction mediated by linc-AhRA. A, The sequence alignment of 117nt 
conserved fragment within linc-AhRA. B-C, The interaction profile for linc-AhRA and TRIM27 (B) or TBK1 (C) analyzed by catRAPID fragments 
(http://service.tartaglialab.com/page/catrapid_group). D, Schematic illustration of constructed deletion mutants of linc-AhRA (left) and immunoblot analysis of TBK1 level in BV2 cells 
transfected with the plasmids expressing the indicated deletion mutants of linc-AhRA for 48 h (right). E, Immunoblot analysis of the indicated factors in the pull-down enrichment of the 
corresponding tRSA-linc-AhRA deletion mutants. F, Immunoblot analysis of TBK1 level in HMC3 cells with a transfection of the plasmids expressing the indicated lncRNAs for 48 h. G, Dual 
luciferase analysis of IFN-β promoter activity in HEK 293T cells with the co-transfection of linc-AhRA deletion mutants expressing plasmids as indicated, a firefly luciferase reporter (IFN-β-Luc) 
and TK-renilla for 30 h and infected with HSV-1 (MOI 1) for another 6 h. H, Co-IP analysis of the TBK1-TRIM27 interaction in HEK 293T cells co-transfected with FLAG-TRIM27, HA-TBK1, 
and 117nt for 42  h, followed by MG-132 treatment (10 μM) for another 6 h. I, Left: Fluorescence microscopy images of viral replication (green) in BV2 cells with EGFP-HSV-1 (MOI 1) 
infection for 24 h, following a transfection of the indicated linc-AhRA deletion mutant or empty control for 48 h. Scale bar, 100 μm. Right: The quantitative result for relative EGFP 
fluorescence intensity obtained from three independent experiments. J, Determination of viral titers in BV2 cells transfected with plasmids expressing the indicated truncation of linc-AhRA 





for 48 h, followed by HSV-1 infection (MOI 1) for 24 h. K, Secondary structure of linc-AhRA conserved 117nt fragment (top) and human homology (bottom) with minimum free energy 
predicted by the Vienna RNA web server. The corresponding ensemble free energy is also labeled. L, qPCR analysis of cytoplasmic and nuclear ratios of linc-AhRA deletion mutants in BV2 cells 
with HSV-1 infection (MOI 1) for 24 h, following a transfection of the indicated linc-AhRA deletion mutant or empty control for 48 h. Data are representative of three independent 
experiments (D[right]-F, H-I), three independent experiments with n = 3 technical replicates (G, J, L), each symbol represents an individual technical replicate (G, J) or one independent 
experiment (I[right])(shown as mean and s.d. in G, I[right], J, L), two-tailed unpaired Student’s t-test (G, I[right], J, L). 
 
Indeed, the 117nt conserved fragment of 
linc-AhRA was sufficient to enhance the interactions 
between TBK1 and TRIM27 in murine microglia 
(Figure 9H). Moreover, the fragments containing the 
117nt region, but not those without the 117nt 
fragment, facilitated HSV-1 infection in BV2 cells, 
confirmed by the EGFP-reporter virus fluorescence 
intensity (Figure 9I) and viral titers (Figure 9J). Given 
the difference in function between linc-AhRA and 
BASP-AS1, we next determined whether the 
conserved 117nt fragment is related to this difference. 
Based on their secondary structure under the 
minimum free energy, it is noteworthy that the 117nt 
fragment is hidden in the secondary structure of 
BASP-AS1, leading to a failure of exposure and the 
formation of two continuous loops (Figure S14A). In 
contrast, the 117nt fragment within linc-AhRA is 
completely exposed, resulting in the successful 
formation of two continuous loops (Figure S14B). 
This difference may lead to the functional difference 
between linc-AhRA and BASP-AS1. Moreover, the 
117nt fragment of linc-AhRA and its human ortholog 
had highly similar structures in their “Y” forms 
(Figure 9K), implying their similar function. 
Interestingly, we also isolated the subcellular fraction 
RNA and unexpectedly found that loss of the 117nt 
fragment led to an impairment of the nuclear export 
of linc-AhRA (Figure 9L), suggesting the conserved 
117nt fragment within linc-AhRA is crucial for their 
nuclear export. 
Microglial linc-AhRA KI mice are 
susceptible to HSV-1 infection and exhibit an 
impaired innate antiviral response 
To explore the role of microglial linc-AhRA upon 
neurotropic virus infection in vivo, we established a 
mouse model with microglia-specific linc-AhRA 
knock-in (KI) at the Rosa26 locus (Figure S15A). 
Cx3cr1-CreERT2 mice, in which the Cx3cr1 promoter 
drives the expression of Cre recombinase fused to an 
estrogen ligand-binding domain, were mated with 
Cre-dependent linc-AhRA KI mice to obtain 
tamoxifen (TAM)-induced microglia-specific 
linc-AhRA KI mice (Figure S15B). To determine the 
efficiency of linc-AhRA KI, we isolated the neurons, 
astrocytes, microglia, peritoneal macrophages, and 
bone marrow-derived macrophages (BMDMs). We 
found that both microglia (29-60-fold change) and 
BMDMs (2-5-fold change) from microglia-specific 
linc-AhRA KI mice expressed high levels of 
linc-AhRA following subcutaneous injection of TAM 
(Figure S16A). We also extracted the RNA from 
various tissues and found that only the brain 
expressed high levels of linc-AhRA following TAM 
treatment in microglial linc-AhRA KI mice (Figure 
S16B). In particular, the cortex and BS isolated from 
linc-AhRA KI mice showed higher levels of 
linc-AhRA than those from control mice (Figure 
S16C). We also investigated astrocytes in the CNS 
using histological immunofluorescence analysis. We 
found that linc-AhRA KI did not affect the 
morphology of glial fibrillary acidic protein (GFAP+) 
astrocytes in all of the brain regions investigated 
(Figure S16D). Flow cytometry analysis results 
showed comparable microglial clusters 
(CD11b+CD45low) in linc-AhRA KI and control mice 
(Figure S16E). We next performed a thorough 
histopathological analysis of different brain regions in 
microglia-specific linc-AhRA KI mice and the 
corresponding control counterparts. We found that 
the microglia-specific linc-AhRA KI mice exhibited no 
abnormalities in their CNS gross anatomy (Figure 
S16F). Histological analyses of the five principal 
organs showed no significant differences between the 
linc-AhRA KI and control mice (Figure S16G). To test 
whether other phenotypes existed in microglia- 
specific linc-AhRA KI mice, we compared the body 
weights and sizes and found no significant differences 
(Figure S16H-I). 
Next, we challenged the microglia-specific 
linc-AhRA KI mice and the corresponding control 
mice with HSV-1 in the brain to establish an HSE 
model (Figure 10A). Of note, the microglia-specific 
linc-AhRA KI mice lost weight rapidly after 
intranasal infection with HSV-1 (Figure 10B) and 
showed higher mortality than the control mice 
(Figure 10C). Moreover, we observed severe disease 
development in microglia-specific linc-AhRA KI mice, 
as demonstrated by disease scores reflecting 
neurological symptoms (Figure 10D), hydrocephalus 
(Figure 10E), and eye swelling (Figure 10F), as well as 
images showing the mice brain (Figure 10G). Given 
an enrichment of viral genomic DNA in the 
trigeminus (TG) and BS in HSV-1-infected mice 
(Figure S17A), which were in accordance with 
previous studies [39, 40], we focused on analyzing the 
viral load in these sections. The results indicated that 
the HSV-1 genomic DNA copy numbers were 
significantly higher in the BS (Figure 10H) and TG 
(Figure 10I) of microglia-specific linc-AhRA KI mice 
than in their control counterparts. Similarly, a higher 
virus titer was also observed in the BS (Figure 10J) 





and TG (Figure 10K) from microglia-specific 
linc-AhRA KI mice than in those from control mice. 
Immunofluorescence with an anti-HSV-1 gB indicated 
that microglia-specific linc-AhRA KI mice had more 
HSV-1 virions than the corresponding control mice in 
the BS, especially in the IBA-1+ microglia (Figure 10L). 
 
 
Figure 10. Microglial linc-AhRA KI mice are susceptible to HSV-1 infection. A, The schematic protocol for inducing microglial linc-AhRA KI and establishing the HSE mice model. 
Microglial linc-AhRA KI mice were intranasally inoculated with HSV-1 (1×107 PFU/mouse). On subsequent days, the mice were weighed daily (B), survival was recorded daily (C), and 
symptoms related to neurological diseases (D), hydrocephalus (E), and eye swelling (F) were scored daily. n= 9-12 mice per group (A-F). g, Photographic records of the right eyes and brain 
symptoms from mice with corresponding d.p.i., n = 7-12 mice per group. H-I, Determination of viral DNA copies in homogenized brain stem (BS) (H, n = 8 mice per group) and trigeminal 
ganglia (TG) (I, n = 6 mice per group) at 9 d.p.i. using qPCR. Determination of HSV-1 titers in BS (J) and TG (K) at 9 d.p.i. using a plaque formation assay, n = 6 mice per group. L, Tissue sections 
from BS of control and microglial linc-AhRA KI mice with HSV-1 infection at 9 d.p.i were stained with HSV-1-gB and IBA-1, n = 7 mice per group. Scale bars, 100 μm. Data are representative 
of three independent experiments (B-L) and each symbol represents an individual mouse (H-K) (shown as mean and s.d. in B-F, H-K). Two-way ANOVA (B, D-F), two-tailed unpaired 
Student’s t-test for H-K, log-rank (Mantel-Cox) test for C. 






Figure 11. Microglial linc-AhRA KI mice exhibited an impaired innate antiviral response upon HSV-1 challenge. A, qPCR analysis of linc-AhRA, Ifnb1, and Cxcl10 expression in 
BS isolated 8 days after infection with HSV-1, n = 7 mice per group. B, qPCR analysis of linc-AhRA, Ifnb1, and Cxcl10 expression in cerebral cortex isolated 8 days after infection with HSV-1, 
n = 7 mice per group. C, BS with or without HSV-1 infection were isolated on day 8 after infection; homogenized and immunoblotted with the indicated antibodies. The typical results from 
three mice per group are shown. D, qPCR analysis of the expression of the indicated genes in microglia acutely isolated 2 days after infection with HSV-1, n = 3 mice per group. E, Tissue 
section from the BS of control and microglial linc-AhRA KI mice isolated 2 days after infection with HSV-1 were stained with TBK1 and a microglia-specific marker IBA-1 (n = 9 mice per group), 
white arrows indicate the IBA-1/TBK1 double-positive cells; Scale bars, 50 μm. F, Quantification of IBA-1/TBK1 double-positive cells. G, Immunoblotting analysis of the indicated genes in 
microglia acutely isolated 8 days after infection with HSV-1. Data are representative of three independent experiments (A-G), each symbol represents an individual mouse (A-B, D, F) (shown 
as mean and s.d. in A-B, D, F). Two-tailed unpaired Student’s t-test (A-B, D, F). 
 
We next determined the role of microglial 
linc-AhRA in the innate antiviral response of mice 
brains against HSV-1 infection. We first analyzed the 
activated morphology of microglia at different times 
points following HSV-1 infection. We found that an 
activated microglia morphology appears at 2 days 
post-infection (d.p.i) in wild-type (WT) mice with 
HSV-1 infection, and the activation is most evident at 
8 d.p.i. (Figure S17B). Therefore, we isolated the brain 
tissue at 8 d.p.i. to analyze the level of I-IFN and ISGs. 
We found a reduction of Ifnb1 and Cxcl10 expression 
in the BS (Figure 11A) and cortex (Figure 11B) from 
microglia-specific linc-AhRA KI mice. The 
immunoblotting results indicated a reduced TBK1 
and STAT1 phosphorylation level in BSs from 
microglia-specific linc-AhRA KI mice (Figure 11C). To 
determine the effect of linc-AhRA on the microglial 
innate antiviral response in vivo at an early stage of 
infection, we also performed acute isolation of 
microglia at 2 d.p.i. to analyze the level of I-IFN and 
ISGs. As demonstrated by the qRT-PCR results, 
microglia acutely isolated from microglia-specific 
linc-AhRA KI mice showed a reduced level of Ifnb1, 
Cxcl10, Isg15, and Mx2 against HSV-1 intranasal 
infection at 2 d.p.i (Figure 11D). 
Further, the tissue immunofluorescence assay 
demonstrated that the microglial linc-AhRA KI mice 
showed a decreased level of TBK1 in IBA-1+ microglia 
in the BS, as reflected by the number of IBA-1 and 
TBK1 double-positive cells (Figure 11E-F). The 
microglia acutely isolated from microglia-specific 
linc-AhRA KI mice exhibited reduced 
phosphorylation of TBK1 and a level of TBK1 (Figure 
11G). Together, microglial linc-AhRA negatively 
regulated the innate antiviral response in the CNS 
upon neurotropic HSV-1 infection, possibly due to the 





reduced TBK1 level in microglia. 
Discussion 
Microglia originate from embryonic yolk sacs 
and are disparate from non-CNS macrophages and 
other CNS macrophages [4], suggesting a difference 
between microglia and other macrophages, as 
revealed by some studies [41]. The current 
understanding of the innate antiviral response 
regulatory network is mainly focused on non-CNS 
macrophage cells. In contrast, the regulation 
mechanisms of innate antiviral response in microglia 
remain largely unknown. Identifying the key 
molecules involved in the innate antiviral response of 
microglia against neurotropic herpesvirus contributes 
to a better understanding of innate immune 
homeostasis in the CNS. We identified linc-AhRA as a 
novel and abundant lncRNA in cultured microglial 
cell lines and primary microglia. linc-AhRA was 
markedly upregulated in microglia upon neurotropic 
virus HSV-1 infection and influenza virus and CVB 
infection. The upregulation depended on 
virus-activated AhR signalling. linc-AhRA initiates a 
feedback loop that suppresses antiviral innate 
immune responses in microglia, facilitating the 
infection of neurotropic herpesvirus in murine 
microglia. Indeed, IFN-β is recently reported to 
activate AhR signalling [42]. We found that numerous 
innate stimuli can induce the expression of 
linc-AhRA, suggesting linc-AhRA-mediated negative 
feedback is an intrinsic pathway inhibiting I-IFN 
initiated by the host but not a specific virus. 
Nevertheless, such a negative feedback loop is 
exploited by the virus to escape innate antiviral 
response. Indeed, AhR can be activated by numerous 
viruses, including SARS-CoV-2 and Zika virus 
[42-44]. AhR signalling is involved in the innate 
antiviral response and viral pathogenesis [42-44]. 
However, the role of AhR-activated non-coding 
transcripts in the innate antiviral response remains 
unknown. linc-AhRA expressed by neurons did not 
exhibit a similar function, suggesting that linc-AhRA 
has a specific function in microglia. Indeed, published 
single-cell RNA-sequencing indicated that microglia, 
but not neurons, expressed high levels of AhR [26, 45], 
which may lead to the loss of a phenotype for the 
AhR-activated non-coding gene in neurons during 
neuronal development. A low level of TRIM27 in 
neurons may also result in this phenotype. 
Nevertheless, I-IFNs generated by microglia 
orchestrate the innate antiviral response for neurons 
[2, 6], suggesting a potential implication of linc-AhRA 
in the innate antiviral response in the CNS. 
The nuclear lncRNA usually modulates the 
expression of targeted genes in the nucleus [46]. 
However, linc-AhRA transcripts obtained from in 
vitro transcription reduced the stability of TBK1 in the 
presence of a protein synthesis inhibitor CHX (Figure 
5F). Moreover, the accumulated linc-AhRA induced 
by HSV-1 can export to cytosol at which linc-AhRA 
interacted with TBK1, a cytosolic factor (Figure 2H-I, 
Figure 7, and Figure 9). Further, the mutant lacking 
conserved 117nt fragment did not show a similar 
function with the entire length of linc-AhRA or locate 
efficiently at cytosol (Figure 9). The function of 
linc-AhRA in the innate antiviral response depended 
on its direct action with TBK1 but not its effect on the 
expression of targeted genes in the nucleus. However, 
the possibility that linc-AhRA regulates cGAS and 
STING is excluded because linc-AhRA cannot bind 
cGAS and STING and viral DNA amount bound by 
cGAS cannot be affected by linc-AhRA. Indeed, the 
mRNA is not an ideal level for the activity regulation 
of TBK1 as a kinase. linc-AhRA acts as a scaffold that 
enhances TRIM27-TBK1 interactions to increase the 
TRIM27-mediated ubiquitin modification of TBK1 
and subsequent degradation in a proteasome- 
dependent manner to suppress the innate antiviral 
response of microglia. Notably, TRIM27 is a recently 
discovered RBP mediated by the SPRY domain [19, 
38], and the role of its RNA-binding activity in the 
innate antiviral response, as well as its lncRNA 
interactors, has yet to be determined. Our study 
showed that linc-AhRA binds to the SPRY domain of 
TRIM27 and the coiled-coil domain of TBK1 in HSV-1- 
infected microglia. In the absence of neurotropic 
HSV-1 infection, linc-AhRA binds to TRIM27 but not 
TBK1. At the late stage of HSV-1 infection, linc-AhRA 
binds to both TBK1 and TRIM27. The knockdown of 
TRIM27 reduces the linc-AhRA-TBK1 interactions 
and the function of linc-AhRA in the microglial innate 
antiviral response, suggesting linc-AhRA-TBK1 
interactions depend on TRIM27. Knockdown of 
linc-AhRA also restored the degradation of TBK1 
induced by HSV-1 infection in the late stage, echoing 
the previous findings that HSV-1 facilitates the 
degradation of TBK1 in the late stage of infection [47]. 
Ubiquitination is ideal for regulating a biological 
process that requires a rapid response, such as virus 
infection. TBK1 is a crucial kinase in the signal 
transduction of the innate antiviral response [9] and 
has been reported to undergo ubiquitination, which 
precisely controls its activity [9-11]. In detail, the E3 
ligase DTX4 mediates the K48-linked 
polyubiquitination and degradation of TBK1 [11]. 
TRIM27 induces TBK1 degradation via K48-linked 
ubiquitination at Lys251 and Lys372 [10]. TRIP 
negatively regulates the antiviral response by 
promoting the proteasomal degradation of TBK1 [48]. 
LncRNAs are increasingly recognized as crucial 





factors in host-virus interaction via numerous 
mechanisms, especially in the innate antiviral 
response [19]. However, relatively few lncRNAs 
target TBK1 [49], and the role of lncRNAs in the 
ubiquitination-based degradation of the key factors of 
innate antiviral response remains obscure. Given that 
lncRNA also participates in the ubiquitination- 
mediated degradation of its targeted protein [50], it is 
not unexpected that lncRNAs are involved in the 
ubiquitination-based stability modulation of innate 
antiviral factors. How does linc-AhRA serve as a 
scaffold to place TRIM27 and TBK1 in the proper 
positions? Are there specific sequences or secondary 
structures that determine the translocation of these 
proteins or the binding of linc-AhRA to specific 
proteins? We can exclude the possibility that the 
nuclear export of TRIM27 and the TBK1-TRIM27 
interaction depend on linc-AhRA for the following 
reasons: 1) TRIM27 interacted with TBK1 in HEK 293T 
cells without linc-AhRA, but linc-AhRA over-
expression significantly strengthened the interaction; 
2) linc-AhRA did not affect the nuclear export of 
TRIM27 induced by HSV-1 infection. Further studies 
are necessary to determine whether linc-AhRA serves 
as a scaffold and functions via conformational 
changes. The structural characterization of protein- 
RNA complexes is a promising approach that should 
uncover detailed information regarding this 
interaction. 
Although the human homologous lncRNA of 
linc-AhRA cannot modulate the innate antiviral 
response of microglia, we identified a 117nt conserved 
functional fragment within linc-AhRA in murine 
microglia. Indeed, numerous studies have 
demonstrated that the RNA-binding domain SPRY is 
required for the function of ubiquitination of most 
TRIM family members [38, 51, 52]. Based on this 
perspective, it is fascinating to investigate whether 
human endogenous lncRNAs mediate TBK1 
degradation, similar to mouse linc-AhRA. RIP 
sequencing for TBK1 or TRIM27 immunoprecipitation 
would identify human lncRNAs that can be 
recognized by TBK1 or TRIM27. The 117nt conserved 
fragment mediates the function of linc-AhRA, 
supported by the following results: 1) The deletion 
mutants containing the 117nt fragment, but not those 
lacking 117nt, could inhibit the innate antiviral 
response of murine microglia, thereby facilitating 
neurotropic virus HSV-1 replication; 2) The deletion 
mutants containing the 117nt fragment, but not those 
lacking 117nt, could bind both TBK1 and TRIM27 as 
well as lead to TBK1 degradation; 3) The 117nt 
fragment is sufficient to enhance TRIM27-TBK1 
interaction; 4) Human and mouse 117nt fragments 
have a highly similar secondary structure with a “Y” 
form; 5) The human ortholog 117nt within BASP-AS1 
cannot be exposed as demonstrated by the secondary 
structure, leading to a failure of BASP-AS1 function in 
the innate antiviral response of human microglia. 
Indeed, the catRAPID prediction indicated that the 
fragment within linc-AhRA with a strong propensity 
for TBK1 and TRIM27 interaction contained the 
conserved 117nt region. Although numerous 
evolutionarily conserved lncRNAs have been 
identified, only a few lncRNAs contain conserved 
functional fragments [20, 21]. Identifying the 
functional fragment that endows lncRNAs with 
cellular activities would be beneficial for the 
development of nucleic acid-based therapeutics 
[53-55]. Therefore, the 117nt-based drugs would be 
ideal candidates for treating autoimmune diseases 
characterized by high levels of I-IFNs, such as 
systemic lupus erythematosus (SLE) and 
Aicardi-Goutières syndrome [56]. Further, although 
linc-AhRA is a nuclear-resident lncRNA in the 
steady-state, we found that HSV-1 infection induced 
the nuclear export of linc-AhRA at the phase when 
linc-AhRA is highly expressed. Indeed, the increased 
linc-AhRA expression from plasmids is also partially 
distributed to the cytoplasm. The linc-AhRA deletion 
mutants lacking the 117nt functional fragment could 
not be exported to the cytoplasm. Therefore, the 117nt 
conserved fragment directs the nuclear export of 
linc-AhRA and determines the binding capacity with 
TBK1 and TRIM27. However, although linc-AhRA 
binds to TRIM27, linc-AhRA cannot affect the nuclear 
export of TRIM27, possibly because not all 
linc-AhRAs interact with TRIM27 or not all TRIM27 
can bind to linc-AhRA. Nevertheless, the cytoplasmic 
translocation of linc-AhRA is required for the 
regulation of the innate antiviral response. Indeed, 
although nuclear lncRNAs are overall more abundant, 
they are less stable than their cytoplasmic 
counterparts [57]. However, the precise mechanism of 
linc-AhRA cytoplasm translocation has yet to be 
determined. In summary, our study provides novel 
insights into the mechanism underlying the negative 
regulation of I-IFN production in microglia by a 
lncRNA, which viruses may exploit for immune 
evasion. 
Materials and Methods 
Key resources 
Detailed information regarding viruses, cell 
lines, antibodies, chemicals (TargetMol, Selleck, 
Macklin, and InvivoGen), and software can be 
obtained from Table S7. Mouse IFN-β ELISA Kit was 
purchased from 4A Biotech Co., Ltd (Cat #CME0116). 





RNA isolation and quantitative real-time PCR 
(qPCR) 
Total RNA from cultured cells with the indicated 
treatments was isolated using TRIzol Reagent 
(TIANGEN, #DP405). One microgram of RNA per 
sample was used for cDNA synthesis with the 
PrimeScript RT Reagent using the gDNA Eraser Kit 
(Takara, #RR047A). qPCR assays were performed in a 
CFX96 Touch Real-Time PCR Detection System 
(Bio-Rad) using a TB Green Premix Ex Taq II Kit 
(Takara, #RR820A) following the manufacturer’s 
instructions. The gene expression levels were 
normalized to the internal housekeeping gene Gapdh. 
All qPCR procedures, including the design of the 
primers, validation of PCR conditions, and 
quantification, were performed according to the 
MIQE guidelines [58]. The gene-specific primers are 
listed in Table S8. For an absolute quantification of 
linc-AhRA, the known copies of linc-AhRA obtained 
from in vitro transcription were subjected to six 
10-fold serial dilutions to create a standard curve to 
monitor RNA purification and amplification. The 
amplified transcripts of linc-AhRA were quantified 
using the comparative Ct method. 
High-throughput lncRNA-seq and data analysis 
Total RNA of primary microglia with and 
without HSV-1 infection was isolated with the TRIzol 
Reagent. RNA degradation and contamination were 
monitored by using 1% agarose gels. The RNA purity 
and integrity were checked using the 
NanoPhotometer® spectrophotometer (IMPLEN, CA, 
USA) and the RNA Nano 6000 Assay Kit with the 
Bioanalyzer 2100 system (Agilent Technologies, CA, 
USA), respectively. The RNA concentration was 
measured using the Qubit® RNA Assay Kit in Qubit® 
2.0 Flurometer (Life Technologies, CA, USA). Three 
micrograms of RNA per sample was used as the input 
material and ribosomal RNA (rRNA) was removed 
using the Epicentre Ribo-zero rRNA Removal Kit 
(Epicentre, USA). Afterward, the rRNA-free residues 
were cleaned further using ethanol precipitation. 
Subsequently, sequence libraries were established 
using the NEBNext Ultra Directional RNA Library 
Prep Kit for Illumina (NEB, Ipswich, MA, USA) 
according to the manufacturer’s instructions and 
purified using the AMPure XP system. The quality of 
the sequence libraries was assessed on the Agilent 
Bioanalyzer 2100 system. The clustering of 
index-coded samples was performed on a cBot 
Cluster Generation System using the TruSeq PE 
Cluster Kit v3-cBot-HS (Illumina) following the 
manufacturer’s recommendations. After cluster 
generation, the libraries were sequenced on an 
Illumina Hiseq 4000 platform (Novogene, Beijing, 
China) with 150-bp paired-end reads. Cuffdiff (v2.1.1) 
was used to calculate the FPKMs for each sample's 
lncRNAs and coding genes [59]. Cuffdiff provides 
statistical routines for determining differential 
expression in digital transcript or gene expression 
data using a model based on a negative binomial 
distribution [59]. The genes that exhibited a fold 
change > 4 with adjusted P <0.05 were filtered as 
differentially expressed genes. All raw data were 
uploaded to GEO (GSE167015). 
Plasmids, siRNA, and transfection 
All plasmids were constructed for this study, 
unless otherwise stated. In detail, the coding 
sequences of cGAS, STING, TBK1, IRF3, MAVS, and 
TRIM27 were amplified from the cDNAs of BV2 cells 
infected with HSV-1 for 12 h and inserted into 
pCMV-HA vector with the ClonExpress Ultra One 
Step Cloning Kit (Vazyme, #C115-01), except for 
TRM27, which was cloned into p3XFLAG-CMV10 
plasmids. The mimic activated IRF3(D) form was 
amplified using HA-IRF3 plasmids and then cloned 
into pCMV-HA plasmids with the Mut Express® 
MultiS Fast Mutagenesis Kit V2 (Vazyme, #C215-01). 
All lncRNA-expressing plasmids were constructed by 
TSINGKE (Beijing, China). The deletion mutants were 
amplified from full-length expression plasmids and 
cloned into the corresponding plasmid using the 
ClonExpress Ultra One Step Cloning Kit. The primers 
for the plasmids constructed in this study are listed in 
Table S9. The validated siRNAs were obtained from 
Sigma (https://www.sigmaaldrich.com/singapore. 
html) and synthesized by GenePharma (Shanghai, 
China). Detailed information regarding the siRNAs is 
presented in Table S10. The transfection of plasmids 
in most cells was performed with jetPEI reagents 
(Polyplus, #PT-114-15) except for the transfection of 
difficult cells, such as BV2 cells, which was performed 
using the TransIT-Jurkat reagent (Mirus, #2120). For 
siRNA transfection, the INTERFERin reagent 
(Polypus Transfection, #PT-409-10) was used 
following the manufacturer’s instructions. 
Dual-luciferase reporter (DLR) assay 
Consistent with our prior study [60], the DLR 
assay was performed according to the manufacturer’s 
instructions for the dual-luciferase assay Kit (Pro-
mega, #E1910). Briefly, the Ifnb1-minimal promoter 
and linc-AhRA promoter were amplified from the 
genome of BV2 then cloned into the promoter-less 
vector pGL4.11[luc2p] encoding the firefly luciferase 
to generate the corresponding promoter-driven 
luciferase reporter plasmids. Next, HEK 293T or BV2 
cells cultured in 24-well plates were transfected with 
the corresponding factor expression plasmids and the 





reporter plasmid pGL4.11[luc2p]-Ifnb1 promoter or 
pGL4.11[luc2p]-linc-AhRA promoter as well as the 
internal control vector pRL-TK-Renilla luciferase. The 
luciferase activity was tested at 36 h post transfection 
using the DLR Assay System and GloMax 20/20 
luminometer (Promega). The relative luciferase 
activity (RLA) was calculated as the ratio of firefly 
luciferase activity to Renilla luciferase activity and 
presented as the fold change relative to the RLA in 
basic vector-transfected cells. The primers used to 
construct the reporter plasmid are presented in Table 
S11. 
Rapid amplification of cDNA ends and 
idedntification of full-length lncRNA 
5’ and 3’ RACE assays were performed using the 
SMARTer RACE 5’/3’ Kit (Clontech, #634858) 
according to the manufacturer’s instructions. Briefly, 
total RNA isolated from HSV-1-infected primary 
microglia was used to synthesize the first-strand 
cDNA. Given that linc-AhRA lacks a polyadenylated 
tail, a poly(A) tail was added using Poly(A) 
Polymerase (Takara, #2180A) for the 3’-first-strand 
cDNA synthesis. The synthesis proceeded using the 
protocol provided in the manufacturer’s instructions. 
The 5’-first-strand cDNA was synthesized with 
random primers. Primers used for the linc-AhRA 
RACE assay were designed based on the known 
sequence obtained from the RNA-sequence results. 
Based on the conserved fragment within linc-AhRA, 
we also designed primers for the BASP-AS1 RACE 
assay to obtain full-length BASP-AS1. Primers for the 
RACE assay are presented in Table S12. 
Viral titer determination, DNA purification, 
and quantification 
Viral titers were determined using the plaque 
assay [60]. Briefly, Vero cells were seeded onto 24-well 
plates then infected with media containing HSV-1 at a 
series of dilutions for 2 h. Subsequently, the virus 
inoculum was removed, added overlay medium 
containing 1% methylcellulose, and the cells were 
incubated for 72 h. The final samples were harvested 
and fixed with 4% paraformaldehyde (PFA) then 
stained with 1% crystal violet. Plaque numbers were 
counted and recorded. Viral DNA isolation and 
quantification were performed based on our prior 
study [60]. Briefly, cells with the corresponding 
treatment were repeated frozen at -80 °C and thawed 
three times. Afterward, the viral DNA was isolated 
using the TIANamp Virus DNA/RNA kit (Transgene, 
Beijing, China, #ER201-01). The purified viral DNA 
were quantified using a qRT-PCR assay. 
Identification of conserved fragment 
Highly conserved fragments within linc-AhRA 
in different species were obtained from UCSC 
(http://genome.ucsc.edu), Multiple Sequence 
Alignment by CLUSTALW (https://www.genome. 
jp/tools-bin/clustalw), and ESPript 3.0 (https:// 
espript.ibcp.fr/ESPript/cgi-bin/ESPript.cgi). In 
detail, the linc-AhRAs were subjected to placental 
mammal basewise conservation analysis among 60 
vertebrates using the PhyloP tool in UCSC. Next, we 
checked the alignment block and obtained the 
detailed sequence information regarding the 
respective alignment block with the highest score. The 
alignment blocks in mice, rats, and humans were 
subjected to multiple sequence alignment with 
CLUSTALW and ESPript to identify the conserved 
fragment. 
RNA subcellular isolation 
RNA subcellular isolation was performed based 
on our previous study with minor modifications [60]. 
Briefly, cells were harvested and washed with ice-cold 
phosphate-buffered saline (PBS) twice. After 
centrifugation at 1000 g for 5 min, removed the 
supernatant. The cell pellets were resuspended using 
100 μL 0.1% v/v NP40 in RNase-free water containing 
10 mM Ribonucleoside Vanadyl Complex (RVC) 
(NEB, #S1402S) and a protease and phosphatase 
inhibitor cocktail (Beyotime, #P1045) by pipetting 
gently. After centrifugation at 5000 × g for 30 sec, the 
supernatant was collected and labelled as the 
cytoplasmic fraction. The pellet was washed five 
times with 200 μL ice-cold 0.1% NP40-PBS with 
centrifugation at 1000 × g for 5 min each time. The 
cells were centrifuged at 5000 × g for 30 s for the last 
time, discarded the supernatant, and labelled the 
pellet as the nucleus. Next, RNA was extracted from 
the nucleus and cytoplasm fractions using the 
EasyPure RNA Kit (Transgen, #ER101) following the 
manufacturer’s instructions. 
Mouse primary microglia isolation and culture 
Mouse primary microglia were purified 
according to the protocol previously described with 
minor modifications [8, 61, 62]. In brief, mice brain 
was dissected from neonatal mice (1-3 days) and 
washed three times with 5 mL ice-cold wash media 
(low-glucose Dulbecco’s Modified Eagle Medium 
(DMEM) supplemented with 1% penicillin- 
streptomycin) to remove blood. Next, both the 
olfactory bulb and cerebellum were removed. The 
meningeal layer was carefully stripped to avoid 
contamination of the monocytes in the blood vessels 
and damage to the cortices. The cortices were digested 
with 3 mL 0.25% trypsin-ethylenediaminetetraacetic 





acid (EDTA; Life Technologies, #25200072) for 20 min 
and dispersed to a single-cell level by passing through 
a cell strainer (70 µm) following the stop digestion by 
DMEM containing 10% FBS. The cell suspension was 
centrifuged at 500 × g for 5 min at 4 °C and 
resuspended with growth medium then cultured at 37 
°C in humidified 5% CO2 and 95% air on poly-D- 
lysine (10 µg/mL) (Beyotime, #C0312)-precoated 75 
cm2 cell culture flasks. The medium was half-replaced 
every 4-5 days. After the cells reached confluence 
(8-10 days), the astrocytes and microglia were isolated 
by mild trypsinization with 0.05% Trypsin-EDTA 
(Life Technologies, #25300054) for 5 min [8, 61]. In 
detail, treatment of the confluent mixed glial cultures 
with 0.05% Trypsin-EDTA resulted in the detachment 
of an intact layer of cells containing almost all of the 
microglia and leaving behind highly enriched 
astrocytes. Over 95% of the microglia cultures 
obtained by the digestion of trypsinization were 
positive for IBA-1. The cellular yield is 4.0×105 
microglia/neonatal mouse. More than 85% of the 
remaining cells were astrocytes, as determined by 
staining with GFAP (not shown). After the isolation 
procedure, the attached microglia were allowed to 
recover for 24 h, and the cells were further plated as 
required for the specific experiments. To obtain 
sufficient primary cells, we collected the primary cells 
from five mice as a mixture to seed plate. 
Acute isolation of microglia from adult mice 
Mononuclear cells were isolated from the CNS as 
previously described with minor optimizations [8, 
63-65]. Antibody-coupled microbeads (Miltenyi 
Biotec, #130-093-634) were used for magnetic affinity 
cell sorting to isolate CD11b+ microglia following 
previous studies [61, 66, 67]. Briefly, murine cerebral 
cortices were isolated, cut into pieces no smaller than 
1 mm3 and incubated in 4 mL Hanks' balanced salt 
solution (HBSS; GIBCO, #C14175500BT) containing 
0.05% (w/v) collagenase type IV (Worthington- 
Biochemical, #LS004186), 0.5% (w/v) dispase II 
(Worthington-Biochemical, #LS02100), 40 µg/mL 
DNAse I (TIANGEN, #RT411), and 20 mM 
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPES) for 30 min at 37 °C. Enzymes were 
inactivated with 4 mL of Ca2+- and Mg2+-free HBSS 
containing 2 mM EDTA and 20 mM HEPES. The 
digested product was gently passed through a P1000 
pipette to obtain a homogeneous cell suspension. The 
contents of a petri dish containing the digest medium 
and brain pieces were poured onto a 70 µm strainer, 
and pieces of the brain were pushed through the filter 
using the plunger of a sterile 5 mL syringe in a 
grinding motion until there was no more tissue 
visible. Next, washed the filter with the wash media 
and the cell strainer was continuously topped up 
during this process to wash through any cells trapped 
in the filter. The cell suspension was centrifuged at 
500 × g for 5 min at 4 °C. The obtained cells were 
resuspended in 30% isotonic Percoll (GE, #17089102) 
containing 40 µg/mL DNAse I in DMEM and 
underlaid with 70% isotonic Percoll in HBSS before 
centrifugation at 600× g for 30 min at 25 °C. Interface 
cells were collected for incubation with 9 mL HBSS 
followed by centrifugation at 900 × g for 20 min to 
remove the density gradient medium. Aspirate 
supernatant and resuspend with 1mL growth 
medium and subsequent PBS (Ca2+ and Mg2+-free) 
containing 2% FBS and 1 mM EDTA to remove the 
growth medium. The cells were incubated with 
CD11b-coupled magnetic beads for 20 min at 4 °C. 
Subsequently, the cells were washed with sorting 
buffer (Miltenyi Biotec, #130-091-376-1), then loaded 
onto MS columns and separated on a MidiMACS 
Separator. After washing using a sorting buffer 
three times, the targeted cells were washed using 
sorting buffer. The purity of the microglia was 
analyzed with a flow cytometer by staining with 
CD11b and CD45. This protocol results in a high 
purification of microglia as reflected by a percentage 
of CD11b+CD45lo cells greater than 85%. Our 
protocol approximately generates a total number of 
2.0×105 to 4.0×105 microglia cells per adult mice 
brain. 
CRISPR-Cas9-mediated knockout of AhR 
To deplete AhR, we designed a single guide 
RNA (sgRNA) that targeted the exon 2 and positioned 
them in the sgRNA scaffold within P×459-SpCas9 
plasmids. The sgRNA-targeting sequence was 5’- 
CGAAATCCTGACCTACGTGCAGG-3’. The cell 
clone was examined by genotyping PCR using the 
following primers: F1, 5’-GTTGCTGTTGCTCTAGT 
TGCAG-3’ coupled with R1, 5’- GATATCAGAA 
GCATGCAGAACG-3’. 
RNA Fluorescence in situ hybridization and 
immunofluorescence microscopy 
RNA-FISH was performed according to the 
protocol provided in the RNA FISH Kit (GenePharma, 
#F04401). In brief, cells were cultured onto confocal 
dishes the day before the experiment. After 
performing the corresponding treatment for each 
group, the samples were washed three times with PBS 
for 3 min followed by fixing with 4% PFA for 15 min 
at room temperature (RT) before permeabilization 
with 100 μL precooled 0.1% Buffer A for 5 min. After 
washing twice with 100 μL PBS for 5 min each time, 
100 μL 2× Buffer C was added to each sample and 
incubated in a 37 °C cell culture incubator for 30 min. 





Buffer C was removed and each sample was 
incubated successively with 100 μL 70%, 85% ethanol, 
and 100% ethanol for 3 min at RT. After drying at RT, 
100 μL diluted 3'-CY3-conjugated linc-AhRA probes 
(50 μg/mL) in 1× Buffer E (Buffer E was preincubated 
at 73℃ for 30 min) was added to each sample. Next, 
the incubated samples were denatured at 73 °C for 5 
min and then placed in a 37℃ incubator overnight. 
After washing with 100 μL 0.1% Buffer F, 2× Buffer C, 
and 1× Buffer C for 5 min, the cell nucleus was 
labelled with 4′,6-diamidino-2-phenylindole (DAPI, 
included in the kit) at RT protected from light. After 
washing twice with PBS for 5 min each time, the 
samples were observed under a Zeiss LSM510 Meta 
confocal system equipped with a 63× oil-immersion 
objective lens (Carl Zeiss, Oberkochen, Germany). The 
fluorescence intensity was quantified using Image J 
software. The probe sequence was CC+TAAAACC 
AGCGGA+TATCT (5’-3’). The “+” label indicates an 
LNA modification at the subsequent base. 
Western Blotting 
Western blotting for this study was similar to the 
procedure in our previous study [60]. Briefly, the 
cultured cells with the indicated treatment were 
harvested and lysed in cell lysis buffer (Beyotime, 
#P0013B) containing a protease and phosphatase 
inhibitor cocktail (Beyotime, #P1045). The lysates 
were normalized to equal amounts of protein using 
the bicinchoninic acid (BCA) Protein Assay Kit 
(Beyotime, #P0011). The proteins were separated by 
sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE, 8%-12% acrylamide) then 
transferred to polyvinylidene difluoride membranes 
(Millipore, #ISEQ00010) followed by blocking with 
5% skimmed milk. The membranes were incubated 
with primary antibodies overnight, followed by 
incubation with anti-mouse (1:6000 dilution), 
anti-rabbit (1:8000 dilution), or anti-goat (1:5000 
dilution) horseradish peroxidase (HRP)-conjugated 
secondary antibodies. The blots were visualized with 
enhanced chemiluminescence (ThermoFisher 
Scientific, #34580) and imaged with a Tanon 5200 
image analysis system (Tanon, Shanghai, China). The 
protein bands were quantified with the ImageJ 
software (Bio-Rad). 
Northern Blotting 
The biotin-labeled single-stranded RNA probe 
for linc-AhRA was designed and synthesized by 
SaiCheng Biotechnology Company (Guangzhou). 
Subsequent hybridization was performed using the 
NorthernMax kit (Thermo Fisher Scientific) following 
the manufacturer’s protocol. The probe sequence for 
linc-AhRA was CGGAUAUCUGUCUUGAUGGUUU 
CAAGGGAGGCAUCGCACCCCAGGCUCACUGCC
UACGUGAUAGCAGAAUCUAAG. 
tRSA RNA Pull-down Assay, silver staining, 
mass spectrometry analysis, and western 
blotting identification 
Given that the addition of the tRNA scaffold to 
tRSA captures RNA-interacting proteins more 
efficiently than the biotinylated transcripts, the tRSA 
RNA pull-down assay was performed in this study in 
accordance with prior studies with minor 
modifications [29, 68]. The reagents for this 
experiment were obtained from the Pierce Magnetic 
RNA-Protein Pull-Down Kit (Pierce, #20164) unless 
otherwise stated. Briefly, linc-AhRA was cloned into a 
pcDNA3.1(+) plasmid with the tRSA tag at the 5’ end. 
The plasmids were linearized as a template for the in 
vitro transcription of tRSA or tRSA-linc-AhRA using 
the Takara in vitro Transcription T7 Kit (Takara, 
#6140). The RNA product was digested using DNase 
(TIANGEN, #RT411) purified using the RNAclean Kit 
(TIANGEN, #DP412). Ten micrograms of purified 
RNAs per reaction was denatured for 5 min at 65℃ in 
RNA structure buffer (10 mM HEPES, 10 mM MgCl2, 
pH 7.0) and slowly cooled to RT. Afterwards, the fold 
RNAs were incubated with 50 μL of Streptavidin 
Dynabeads for 20 min at RT in the presence of RVC 
(10 mM) (NEB, #S1402S). BV2 cells (2.0×106) were 
harvested in 300 μL lysis buffer (Beyotime, #P0013) 
with 1 mM phenylmethylsulfonyl fluoride (PMSF; 
Beyotime, #ST505) and protease inhibitor (Beyotime, 
#P1008) by sonicating five times for 10 s with an 
interval of 1 min on ice and then centrifuged at 12,000 
g for 10 min at 4 °C. The supernatant was pre-cleared 
by incubation with 50 μL Streptavidin Dynabeads for 
20 min at 4 °C. Afterwards, the pre-cleared lysate was 
incubated with the folded RNAs for 2 h at 4 °C in 
Protein-RNA Binding Buffer. After washing four 
times (5 mins each) with Wash Buffer containing 10 
mM RVC, 40 μL Elution Buffer was added to the 
magnetic beads and incubated for 30 min at 37 °C to 
obtain pull-down enriched proteins. Subsequently, 
added SDS loading buffer to the enriched proteins 
followed by separation with SDS-PAGE gel 
(Beyotime, #P0012A). Finally, the gel was stained 
using the Fast Silver Stain Kit (Beyotime, #P0017S) 
according to the manufacturer’s instructions. The 
specific bands in tRSA-linc-AhRA compared to those 
in tRSA were cut, and the targeted protein was 
identified using MS. The pull-down enriched proteins 
were confirmed by western blotting. The primers for 
constructing plasmids for the RNA pull-down assay 
are presented in Table S13. 





RNA immunoprecipitation assay 
The RNA immunoprecipitation assay was 
performed using the Magna RIP RNA-Binding 
Protein Immunoprecipitation Kit (Millipore, #17-701) 
following the manufacturer’s instructions with minor 
optimizations. In brief, 115 μL RIP Lysis Buffer 
containing RNase inhibitor and protease inhibitor was 
added to each 15 cm plate with 2.0 × 107 BV2 cells and 
incubated on ice for 5 min to increase the size of the 
cells. The cell lysates were collected and frozen once at 
-80 °C. Then, 50 μL of magnetic beads was mixed with 
5 μg primary antibody or negative control IgG and 
incubated for 30 min at RT with rotation. 
Subsequently, the lysates were quickly thawed and 
centrifuged at 14,000 g for 10 min at 4 °C. Afterwards, 
100 μL of the supernatant was transferred to 
antibody-coupled beads and incubated overnight at 4 
°C with rotation. In addition, 10 µL of the RIP lysate 
supernatant was removed, placed in a new tube, and 
marked as “10% input”. Next, the beads were washed 
with RIP Wash Buffer six times, and the samples were 
digested with proteinase K at 55 °C for 30 min. 
Finally, the RNA was purified with phenol: 
chloroform: isoamyl alcohol (125:24:1, pH = 4.3) 
(Aladdin, #P120621) and the enrichment of specific 
RNAs was analyzed with the One Step TB Green® 
PrimeScript™ RT-PCR Kit II (TAKAR, #RR086A). The 
amount of immunoprecipitated RNAs was 
represented as the fold change of the amount of IgG 
enriched RNA. All the materials were included in the 
RIP Kit unless otherwise stated. 
Cleavage under targets and tagmentation 
(CUT&Tag) 
Given that only a small sample of primary 
microglia was acutely isolated from the mice brain, 
we performed the enzyme-tethering strategy known 
as CUT&Tag [69] to confirm that AhR binds to the 
promoter of linc-AhRA in vivo following the 
instructions for the Novo CUT&Tag High-Sensitivity 
Kit (Novoprotein, #N259-YH0) with minor 
optimizations. Briefly, cells were harvested, counted, 
and centrifuged for 3 min at 600 × g at RT. Next, cells 
were washed twice in 1.2 mL Wash Buffer containing 
a protease inhibitor cocktail by gentle pipetting and 
collected by minor centrifugation at 300 × g for 3 min. 
Of note, removed the supernatant, and the cells were 
resuspended in 800 µL pre-cooled antibody buffer 
containing 1.5 μg primary antibody. Primary antibody 
incubation was performed on a rotating platform for 2 
h at RT. A corresponding secondary antibody was 
diluted 1:100 in 100 µL of Dig-Wash buffer and 
incubated with the cells at RT for 30 min to increase 
the number of Protein A binding sites for each bound 
antibody. Then, we prepared a 1:250 dilution of 
pA-Tn5 adapter complex in Dig-300 Buffer. After 
removing the supernatant by centrifugation at 300 × g 
for 3 min, 100 µL was added to the cells with gentle 
vortexing and incubated with pA-Tn5 at RT for 1 h. 
The cells were washed three times for 10 mins upside 
down in 0.8 mL Dig-med Buffer to remove unbound 
pA-Tn5 protein. Next, the cells were resuspended in 
300 µL tagmentation buffer and incubated at 37 °C for 
1 h. For an interruption of tagmentation, 10 µL of 0.5 
M EDTA, 3 µL of 10% SDS, and 2.5 µL of 20 mg/mL 
Proteinase K was added to 300 µL of the sample, 
which was incubated at 50 °C for 1 h to deactivate 
Proteinase K. Afterwards, added 300 µL Phenol- 
Chloroform-Isoamyl Alcohol (25:24:1) (BioFlux, 
#BSA03M1) to each tube followed by vortexing. The 
sample was transferred to a phase-lock tube for 
centrifugation at 16000 × g for 3 min. Next, 300 µL 
chloroform was added to each sample, inverted 10 
times, and centrifuged at 16000 × g for 3 min at RT. 
The aqueous phase from each tube was separately 
pipetted into a 1.5 ml tube containing 750 μl of 100% 
ethanol and mixed well with a pipette tip. After 
cooling on ice, the samples were centrifuged at 16000 
x g for 15 min at 4℃. Removed the supernatant and 1 
mL 100% ethanol was used to wash each sample by 
centrifuging at 16000 × g for 1 min. After drying, 
added 30 µL TE-RA buffer to each sample to resolve 
the DNA. The final products were subjected to qPCR 
analysis. The primers for CUT&Tag detection are 
provided in Table S14. 
Immunoprecipitation 
Immunoprecipitation assays were performed 
following our previous studies with optimization [60]. 
In brief, cells were harvested then lysed using IP lysis 
buffer (Beyotime, # P0013) containing 1 mM PMSF 
and a proteasome inhibitor cocktail (Beyotime, 
#P1008). Pre-cleared cell lysis was performed by 
incubation with agarose-coupled IgG antibodies to 
remove non-specific binding factors. Pre-cleared 
lysates were added to primary antibodies or 
antibody-coupled agarose and incubated with 
rotation overnight at 4 °C. The sample was 
centrifuged for 30 seconds at 4 °C, and the pellet was 
washed three times using pre-cold lysis buffer 
containing 1 mM PMSF. The washed sample was 
centrifuged at 500 g and 4 °C for 30 sec. The last pellet 
was centrifuged at 500 g and 4 °C for 2 min. After 
aspirating the supernatant, the pellet was 
resuspended in 50 μL 1×SDS loading buffer and 
vortexed. The sample was heated to 100 °C for 5 min 
and micro centrifuged for 1 min at 14,000 × g. The 
supernatant was then subjected to immunoblotting 
analysis. To reduce the appearance of denatured IgG 
heavy chains on the indicated bands, secondary 





antibodies including IPkine HRP AffiniPure Goat 
Anti-Mouse IgG Light Chain (Abbkine, #A25022) and 
IPkine HRP AffiniPure Mouse Anti-Rabbit IgG Light 
Chain (Abbkine, #A25012) were used according to the 
manufacturer’s instructions. 
Immunofluorescence assay 
The immunofluorescence assay was performed 
following our previous study with minor 
modifications [60]. In brief, cells were harvested 
following the corresponding treatment and washed 
with PBS. Afterwards, the cells were fixed with 4% 
PFA, followed by washing with PBS. Next, the 
samples were permeabilized with 0.1% NP-40 for 4 
min and washed with PBS. After being blocked with 
5% bovine serum albumin (BSA) for 90 min, the 
samples were washed and subsequently stained with 
primary antibody overnight at 4 °C followed by 
incubation with the Alexa Fluor conjugated secondary 
antibody (Life Technologies) at RT. The nuclei were 
labelled using DAPI (Beyotime, #C1005). Fluores-
cence images were captured using a Zeiss LSM510 
Meta confocal system (Carl Zeiss, Oberkochen, 
Germany) to visualize the co-localization of TRIM27 
and TBK1. To analyze the replication of the EGFP 
reporter virus, we harvested the samples and 
observed them using the NIS-Elements Viewer 
(Nikon, Japan) and quantified them using Image J 
software. 
Antisense LNA long RNA GapmeRs design and 
application 
Antisense LNA GapmeR targeting linc-AhRA 
was produced according to a custom design 
generated by a proprietary design software for 
optimal performance [70, 71] (https://geneglobe. 
qiagen.com/us/customize/rna-silencing/antisense-l
na-gapmers). All potential LNA GapmeRs were 
ranked according to their design score, with 1 being 
the best score. The GapmeRs with a score in the top 3 
and negative control LNA were selected for synthesis 
by QIAGEN. 5’ and 3’ modifications were indicated 
within the product sequence (Table S15). The 
antisense LNA GapmeRs contains phosphonothioate 
backbone modifications indicated by “*” in the 
product sequence, and the position of the LNA 
modification is not shown. The jetPEI transfection 
reagent (Polyplus, #PT-114-15) was used to obtain 
LNA oligonucleotides (60 pM), and the cells were 
maintained in the medium used for transfection for 24 
h. Afterwards, the transfection medium was replaced 
with a fresh medium to maximize cell viability. After 
transfecting for 2 h, the knockdown efficiency of the 
LNA GapmeRs against linc-AhRA was assessed using 
qRT-PCR. The LNAs with high efficiency after 
knocking down linc-AhRA were selected for 
subsequent experiments. 
Mice generation 
Our mice model was generated using a 
CRISPR-Cas9 system with a C57BL/6J mouse 
background by the Shanghai Model Organisms 
Center. Briefly, a CAG promoter and a promoter-less 
linc-AhRA gene were introduced into the 
well-defined Rosa26 locus by homology 
recombination. The donor vector containing a 3.3 kb 5′ 
homology arm, a linc-AhRA gene expression cassette 
with floxed-STOP-floxed (CAG-LSL-linc-AhRA-WPRE- 
polyA), and a 3.3 kb 3′ homology arm was cloned. 
Cas9 mRNA was transcribed in vitro with an 
mMESSAGE mMACHINE T7 Ultra Kit (Ambion) and 
subsequently purified using a MEGAclear Kit 
(Thermo Fisher). 5′-GGGGACACACTAAGGGA 
GCT-3′ was chosen as the single guide RNA targeting 
Rosa26, in vitro transcribed using a MEGAshortscript 
Kit (Thermo Fisher), and purified using a MEGAclear 
Kit. A donor vector with guide RNA and Cas9 mRNA 
was microinjected into C57BL/6J fertilized eggs. Mice 
(F0 generation) positive for homologous 
recombination were identified using long PCR. The 
genomic DNA for genotyping (FOREGENE, 
#TP-01341) was prepared from mouse tails. The 
primers used for genotyping are shown in Table S16 
(linc-AhRA) and Table S17 (Cre). The F0 mice were 
crossed with C57BL/6J mice to obtain heterozygous 
Cre-dependent linc-AhRA KI mice (F1 generation). 
Positive (#3, 4, 5, 6, 7) mice (F1 generation) were again 
identified with long PCR. We crossed Cre-dependent 
linc-AhRA KI mice with Cx3cr1creERT2 mice to obtain 
TAM-induced microglia-specific linc-AhRA KI 
(Cx3cr1creERT2:Rosa26-LSL-linc-AhRA) mice. 
Mice model of HSV-1 brain infection 
We used microglia linc-AhRA KI mice to assess 
the role of microglial linc-AhRA in the CNS innate 
antiviral response. To initiate the expression of 
linc-AhRA, 6–7-week-old male mice were injected 
subcutaneously with 4 mg TAM in 200 µl warm corn 
oil at two time points 48 h apart. Homozygous 
Cre-dependent microglial linc-AhRA KI male mice 
were Cx3cr1creERT2-negative (Cx3cr1creERT2-negative 
Rosa26-LSL-linc-AhRA) were used as littermate 
controls. The mice were randomly allocated into 
different experimental groups and the investigators 
were blinded to mice allocation during the 
experiments. The microglia-specific linc-AhRA KI and 
control mice were intranasally inoculated with HSV-1 
(1×107 PFU/mouse) and the weights of all mice were 
recorded daily along with their HSE symptoms. The 
scoring rules for HSE symptoms were based on 





previous studies [2, 72] with minor modifications: hair 
loss (0: none, 1: minimal periocular hair loss, 2: 
moderate periocular hair loss, 3: severe hair loss 
limited to the periocular region, 4: severe and 
extensive hair loss); hydrocephalus (0: none, 1: minor 
bump, 2: moderate bump, 3: large bump); symptoms 
related to neurological disease (0: normal, 1: jumpy, 2: 
uncoordinated, 3: hunched/lethargic, 4: unres-
ponsive/no movement); eye swelling/lesions (0: 
none, 1: one eye with minor swelling, 2: one eye with 
moderate swelling, 3: one eye with severe swelling 
and skin lesions, 4: two eyes with swelling). The mice 
were sacrificed for histological analysis and virus 
quantification when a body-weight reduction of 30% 
occurred. For histological analysis, mice were 
perfused with cold PBS and in succession with 4% 
PFA. Subsequently, the whole brain was dissected, 
fixed in 4% PFA solution, embedded in paraffin, 
sectioned, stained with hematoxylin-eosin solution or 
anti-HSV-1 antibody and examined under light 
microscopy. The levels of TBK-1 in the microglia were 
analyzed by IBA-1 and TBK1 staining in the BS section 
followed by observation using a fluorescence 
microscope to determine the ratio of IBA-1+TBK-1+ 
positive cells. For virus quantification, tissues were 
dissected and prepared in a 10% DMEM-based 
solution. After these samples were repeatedly frozen 
three times, the HSV-1 abundance was determined 
using plaque formation assays and qPCR-based 
HSV-1 genomic DNA copy numbers. To determine 
the effect of microglial linc-AhRA on the innate 
antiviral response in the CNS, the tissue RNAs were 
extracted using TRIzol reagent. The levels of 
I-IFN-associated genes were analyzed. Protein 
samples of the BS were also prepared in RIPA buffer 
to analyze I-IFN signaling activation in the mice brain. 
We also investigated the effect of linc-AhRA on the 
innate antiviral response of microglia upon HSV-1 
infection at the early stage. The microglia in the BS of 
all groups at 2 d.p.i. were sorted using anti-CD11b+ 
antibody-coupled microbeads following prior studies 
with minor modifications [61, 66, 67]. Total RNA 
from microglia was extracted using the RNAprep 
Pure Micro Kit (TIANGEN, #DP420). The mRNA 
expression of the corresponding innate antiviral 
genes was determined using qRT-PCR. Kept all mice 
under a 12-h day and light cycle. All mice experiments 
were performed under the guidelines for Laboratory 
Animal Science at Jinan University. No data were 
excluded. 
Statistical analysis 
Detailed information regarding the statistical 
analysis for the data are described in corresponding 
figure legends. We used GraphPad Prism version 8.0 
to perform statistical analyses. P values less than 0.05 
were considered statistically significant. n.s, not 
significant, * P < 0.05, ** P < 0.01. 
Supplementary Material  
Supplementary figures and tables. 
http://www.thno.org/v11p9623s1.pdf  
Acknowledgments 
This work was supported by grants from the 
National Natural Science Foundation of China (No. 
81872908 and 82072274), Key Laboratory of Virology 
of Guangdong province, Guangdong Provincial 
Natural Science Foundation Project (No. 2019A1 
515010046), and Guangdong Modern Agricultural 
Industrial Technology System Innovation Team (No. 
2017YFC1701100). 
Author Contributions 
Yiliang Wang and Weisheng Luo: conception 
and design, collection and/or assembly of data, data 
analysis and interpretation, and manuscript writing; 
Lianzhou Huang, Ji Xiao, Xiaowei Song, Xiaohui 
Wang, Yuying Ma, Ping Liu, and Yexuan Zhu: 
collection and/or assembly of data and data analysis 
and interpretation; Fujun Jin, Kaio Kitazato, Zhe Ren, 
and Yifei Wang: final interpretation of the manuscript. 
All authors approved the final manuscript and agreed 
to this publication. 
Competing Interests 
The authors have declared that no competing 
interest exists. 
References 
1. Cao X. Self-regulation and cross-regulation of pattern-recognition receptor 
signalling in health and disease. Nat Rev Immunol. 2016; 16: 35-50. 
2. Reinert LS, Lopuå nK, Winther H, Sun C, Thomsen MK, Nandakumar R, et al. 
Sensing of HSV-1 by the cGAS-STING pathway in microglia orchestrates 
antiviral defence in the CNS. Nature Communications. 2016; 7: 13348. 
3. Wang P, Xu J, Wang Y, Cao X. An interferon-independent lncRNA promotes 
viral replication by modulating cellular metabolism. Science. 2017; 358: 1051-5. 
4. Colonna M, Butovsky O. Microglia Function in the Central Nervous System 
During Health and Neurodegeneration. Annu Rev Immunol. 2017; 35: 441-68. 
5. Wang Y, Wang Z, Wang Y, Li F, Jia J, Song X, et al. The Gut-Microglia 
Connection: Implications for Central Nervous System Diseases. Front 
Immunol. 2018; 9: 2325. 
6. Wang Y, Jia J, Wang Y, Li F, Song X, Qin S, et al. Roles of HSV-1 
infection-induced microglial immune responses in CNS diseases: friends or 
foes? Crit Rev Microbiol. 2019; 45: 581-94. 
7. Chhatbar C, Detje CN, Grabski E, Borst K, Spanier J, Ghita L, et al. Type I 
Interferon Receptor Signaling of Neurons and Astrocytes Regulates Microglia 
Activation during Viral Encephalitis. Cell Rep. 2018; 25: 118-29 e4. 
8. Rothhammer V, Borucki DM, Tjon EC, Takenaka MC, Chao CC, 
Ardura-Fabregat A, et al. Microglial control of astrocytes in response to 
microbial metabolites. Nature. 2018; 557: 724-8. 
9. Ahmad L, Zhang SY, Casanova JL, Sancho-Shimizu V. Human TBK1: A 
Gatekeeper of Neuroinflammation. Trends Mol Med. 2016; 22: 511-27. 
10. Zheng Q, Hou J, Zhou Y, Yang Y, Xie B, Cao X. Siglec1 suppresses antiviral 
innate immune response by inducing TBK1 degradation via the ubiquitin 
ligase TRIM27. Cell Res. 2015; 25: 1121-36. 
11. Cui J, Li Y, Zhu L, Liu D, Songyang Z, Wang HY, et al. NLRP4 negatively 
regulates type I interferon signaling by targeting the kinase TBK1 for 
degradation via the ubiquitin ligase DTX4. Nat Immunol. 2012; 13: 387-95. 





12. Song G, Liu B, Li Z, Wu H, Wang P, Zhao K, et al. E3 ubiquitin ligase RNF128 
promotes innate antiviral immunity through K63-linked ubiquitination of 
TBK1. Nat Immunol. 2016; 17: 1342-51. 
13. Cai J, Chen HY, Peng SJ, Meng JL, Wang Y, Zhou Y, et al. USP7-TRIM27 axis 
negatively modulates antiviral type I IFN signaling. FASEB J. 2018; 32: 
5238-49. 
14. Aubert M, Strongin DE, Roychoudhury P, Loprieno MA, Haick AK, Klouser 
LM, et al. Gene editing and elimination of latent herpes simplex virus in vivo. 
Nat Commun. 2020; 11: 4148. 
15. Yin D, Ling S, Wang D, Dai Y, Jiang H, Zhou X, et al. Targeting herpes simplex 
virus with CRISPR-Cas9 cures herpetic stromal keratitis in mice. Nat 
Biotechnol. 2021. 
16. Wang Y, Song X, Wang Y, Huang L, Luo W, Li F, et al. Dysregulation of 
cofilin-1 activity-the missing link between herpes simplex virus type-1 
infection and Alzheimer's disease. Crit Rev Microbiol. 2020; 46: 381-96. 
17. Sun D, Yu Z, Fang X, Liu M, Pu Y, Shao Q, et al. LncRNA GAS5 inhibits 
microglial M2 polarization and exacerbates demyelination. EMBO Rep. 2017; 
18: 1801-16. 
18. Zhang Y, Cao X. Long noncoding RNAs in innate immunity. Cell Mol 
Immunol. 2016; 13: 138-47. 
19. Wang Y, Wang Y, Luo W, Song X, Huang L, Xiao J, et al. Roles of long 
non-coding RNAs and emerging RNA-binding proteins in innate antiviral 
responses. Theranostics. 2020; 10: 9407-24. 
20. Huarte M, Guttman M, Feldser D, Garber M, Koziol MJ, Kenzelmann-Broz D, 
et al. A large intergenic noncoding RNA induced by p53 mediates global gene 
repression in the p53 response. Cell. 2010; 142: 409-19. 
21. Tsai MC, Manor O, Wan Y, Mosammaparast N, Wang JK, Lan F, et al. Long 
noncoding RNA as modular scaffold of histone modification complexes. 
Science. 2010; 329: 689-93. 
22. Hudson WH, Pickard MR, de Vera IM, Kuiper EG, Mourtada-Maarabouni M, 
Conn GL, et al. Conserved sequence-specific lincRNA-steroid receptor 
interactions drive transcriptional repression and direct cell fate. Nat Commun. 
2014; 5: 5395. 
23. Kang YJ, Yang DC, Kong L, Hou M, Meng YQ, Wei L, et al. CPC2: a fast and 
accurate coding potential calculator based on sequence intrinsic features. 
Nucleic Acids Res. 2017; 45: W12-W6. 
24. Zhou Y, Li M, Xue Y, Li Z, Wen W, Liu X, et al. Interferon-inducible 
cytoplasmic lncLrrc55-AS promotes antiviral innate responses by 
strengthening IRF3 phosphorylation. Cell Res. 2019; 29: 641-54. 
25. Tan C, Takada S. Dynamic and Structural Modeling of the Specificity in 
Protein-DNA Interactions Guided by Binding Assay and Structure Data. J 
Chem Theory Comput. 2018; 14: 3877-89. 
26. Vanlandewijck M, He L, Mae MA, Andrae J, Ando K, Del Gaudio F, et al. A 
molecular atlas of cell types and zonation in the brain vasculature. Nature. 
2018; 554: 475-80. 
27. Garber M, Yosef N, Goren A, Raychowdhury R, Thielke A, Guttman M, et al. 
A high-throughput chromatin immunoprecipitation approach reveals 
principles of dynamic gene regulation in mammals. Mol Cell. 2012; 47: 810-22. 
28. Zheng Q, Hou J, Zhou Y, Li Z, Cao X. The RNA helicase DDX46 inhibits innate 
immunity by entrapping m(6)A-demethylated antiviral transcripts in the 
nucleus. Nat Immunol. 2017; 18: 1094-103. 
29. Iioka H, Loiselle D, Haystead TA, Macara IG. Efficient detection of RNA–
protein interactions using tethered RNAs. Nucleic Acids Research. 2011; 39: 
e53-e. 
30. Zhang M, Wang L, Zhao X, Zhao K, Meng H, Zhao W, et al. TRAF-interacting 
protein (TRIP) negatively regulates IFN-beta production and antiviral 
response by promoting proteasomal degradation of TANK-binding kinase 1. J 
Exp Med. 2012; 209: 1703-11. 
31. Wang J, Zhang Y, Li Q, Zhao J, Yi D, Ding J, et al. Influenza Virus Exploits an 
Interferon-Independent lncRNA to Preserve Viral RNA Synthesis through 
Stabilizing Viral RNA Polymerase PB1. Cell Rep. 2019; 27: 3295-304 e4. 
32. Nguyen ML, Blaho JA. Apoptosis during herpes simplex virus infection. Adv 
Virus Res. 2007; 69: 67-97. 
33. Ning X, Wang Y, Jing M, Sha M, Lv M, Gao P, et al. Apoptotic Caspases 
Suppress Type I Interferon Production via the Cleavage of cGAS, MAVS, and 
IRF3. Mol Cell. 2019; 74: 19-31 e7. 
34. Wang Y, Ning X, Gao P, Wu S, Sha M, Lv M, et al. Inflammasome Activation 
Triggers Caspase-1-Mediated Cleavage of cGAS to Regulate Responses to 
DNA Virus Infection. Immunity. 2017; 46: 393-404. 
35. Zheng Y, Liu Q, Wu Y, Ma L, Zhang Z, Liu T, et al. Zika virus elicits 
inflammation to evade antiviral response by cleaving cGAS via NS1-caspase-1 
axis. EMBO J. 2018; 37. 
36. Bellucci M, Agostini F, Masin M, Tartaglia GG. Predicting protein associations 
with long noncoding RNAs. Nat Methods. 2011; 8: 444-5. 
37. Agostini F, Zanzoni A, Klus P, Marchese D, Cirillo D, Tartaglia GG. catRAPID 
omics: a web server for large-scale prediction of protein-RNA interactions. 
Bioinformatics. 2013; 29: 2928-30. 
38. Williams FP, Haubrich K, Perez-Borrajero C, Hennig J. Emerging 
RNA-binding roles in the TRIM family of ubiquitin ligases. Biol Chem. 2019; 
400: 1443-64. 
39. Marcocci ME, Napoletani G, Protto V, Kolesova O, Piacentini R, Li Puma DD, 
et al. Herpes Simplex Virus-1 in the Brain: The Dark Side of a Sneaky Infection. 
Trends Microbiol. 2020; 28: 808-20. 
40. Jennische E, Eriksson CE, Lange S, Trybala E, Bergstrom T. The anterior 
commissure is a pathway for contralateral spread of herpes simplex virus type 
1 after olfactory tract infection. J Neurovirol. 2015; 21: 129-47. 
41. Bodda C, Reinert LS, Fruhwurth S, Richardo T, Sun C, Zhang BC, et al. HSV1 
VP1-2 deubiquitinates STING to block type I interferon expression and 
promote brain infection. J Exp Med. 2020; 217. 
42. Liu Y, Lv J, Liu J, Li M, Xie J, Lv Q, et al. Mucus production stimulated by 
IFN-AhR signaling triggers hypoxia of COVID-19. Cell Res. 2020; 30: 1078-87. 
43. Yamada T, Horimoto H, Kameyama T, Hayakawa S, Yamato H, Dazai M, et al. 
Constitutive aryl hydrocarbon receptor signaling constrains type I 
interferon-mediated antiviral innate defense. Nat Immunol. 2016; 17: 687-94. 
44. Giovannoni F, Bosch I, Polonio CM, Torti MF, Wheeler MA, Li Z, et al. AHR is 
a Zika virus host factor and a candidate target for antiviral therapy. Nat 
Neurosci. 2020; 23: 939-51. 
45. He L, Vanlandewijck M, Mae MA, Andrae J, Ando K, Del Gaudio F, et al. 
Single-cell RNA sequencing of mouse brain and lung vascular and 
vessel-associated cell types. Sci Data. 2018; 5: 180160. 
46. Sun Q, Hao Q, Prasanth KV. Nuclear Long Noncoding RNAs: Key Regulators 
of Gene Expression. Trends Genet. 2018; 34: 142-57. 
47. Sallam T, Jones M, Thomas BJ, Wu X, Gilliland T, Qian K, et al. Transcriptional 
regulation of macrophage cholesterol efflux and atherogenesis by a long 
noncoding RNA. Nat Med. 2018; 24: 304-12. 
48. Lin M, Zhao Z, Yang Z, Meng Q, Tan P, Xie W, et al. USP38 Inhibits Type I 
Interferon Signaling by Editing TBK1 Ubiquitination through NLRP4 
Signalosome. Mol Cell. 2016; 64: 267-81. 
49. Wang Y, Wang P, Zhang Y, Xu J, Li Z, Li Z, et al. Decreased Expression of the 
Host Long-Noncoding RNA-GM Facilitates Viral Escape by Inhibiting the 
Kinase activity TBK1 via S-glutathionylation. Immunity. 2020; 53: 1168-81 e7. 
50. Li Y, Yuan J, Chen F, Zhang S, Zhao Y, Chen X, et al. Long noncoding RNA 
SAM promotes myoblast proliferation through stabilizing Sugt1 and 
facilitating kinetochore assembly. Nat Commun. 2020; 11: 2725. 
51. Choudhury NR, Heikel G, Trubitsyna M, Kubik P, Nowak JS, Webb S, et al. 
RNA-binding activity of TRIM25 is mediated by its PRY/SPRY domain and is 
required for ubiquitination. BMC Biol. 2017; 15: 105. 
52. Sanchez JG, Sparrer KMJ, Chiang C, Reis RA, Chiang JJ, Zurenski MA, et al. 
TRIM25 Binds RNA to Modulate Cellular Anti-viral Defense. J Mol Biol. 2018; 
430: 5280-93. 
53. Hosono Y, Niknafs YS, Prensner JR, Iyer MK, Dhanasekaran SM, Mehra R, et 
al. Oncogenic Role of THOR, a Conserved Cancer/Testis Long Non-coding 
RNA. Cell. 2017; 171: 1559-72 e20. 
54. Fiorenzano A, Pascale E, Gagliardi M, Terreri S, Papa M, Andolfi G, et al. An 
Ultraconserved Element Containing lncRNA Preserves Transcriptional 
Dynamics and Maintains ESC Self-Renewal. Stem Cell Rep. 2018; 10: 1102-14. 
55. Lin N, Chang KY, Li Z, Gates K, Rana ZA, Dang J, et al. An evolutionarily 
conserved long noncoding RNA TUNA controls pluripotency and neural 
lineage commitment. Mol Cell. 2014; 53: 1005-19. 
56. Rodero MP, Crow YJ. Type I interferon-mediated monogenic 
autoinflammation: The type I interferonopathies, a conceptual overview. J Exp 
Med. 2016; 213: 2527-38. 
57. Bridges MC, Daulagala AC, Kourtidis A. LNCcation: lncRNA localization and 
function. J Cell Biol. 2021; 220. 
58. Bustin SA, Vladimir B, Garson JA, Jan H, Jim H, Mikael K, et al. The MIQE 
guidelines: minimum information for publication of quantitative real-time 
PCR experiments. Clinical Chemistry. 2009; 55: 611. 
59. Cole T, Williams BA, Geo P, Ali M, Gordon K, Baren MJ, Van, et al. Transcript 
assembly and quantification by RNA-Seq reveals unannotated transcripts and 
isoform switching during cell differentiation. Nature Biotechnology. 2010; 28: 
511-5. 
60. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics 
of Coronavirus Disease 2019 in China. N Engl J Med. 2020; 382: 1708-20. 
61. Mayo L, Trauger SA, Blain M, Nadeau M, Patel B, Alvarez JI, et al. Regulation 
of astrocyte activation by glycolipids drives chronic CNS inflammation. Nat 
Med. 2014; 20: 1147-56. 
62. van Loo G, De Lorenzi R, Schmidt H, Huth M, Mildner A, Schmidt-Supprian 
M, et al. Inhibition of transcription factor NF-kappaB in the central nervous 
system ameliorates autoimmune encephalomyelitis in mice. Nat Immunol. 
2006; 7: 954-61. 
63. Erny D, Hrabe de Angelis AL, Jaitin D, Wieghofer P, Staszewski O, David E, et 
al. Host microbiota constantly control maturation and function of microglia in 
the CNS. Nat Neurosci. 2015; 18: 965-77. 
64. Thion MS, Low D, Silvin A, Chen J, Grisel P, Schulte-Schrepping J, et al. 
Microbiome Influences Prenatal and Adult Microglia in a Sex-Specific Manner. 
Cell. 2018; 172: 500-16 e16. 
65. Stark JC, Wallace E, Lim R, Leaw B. Characterization and Isolation of Mouse 
Primary Microglia by Density Gradient Centrifugation. J Vis Exp. 2018: 
e57065. 
66. Sharma K, Schmitt S, Bergner CG, Tyanova S, Kannaiyan N, Manrique-Hoyos 
N, et al. Cell type- and brain region-resolved mouse brain proteome. Nat 
Neurosci. 2015; 18: 1819-31. 
67. Kleinberger G, Yamanishi Y, Suarez-Calvet M, Czirr E, Lohmann E, Cuyvers 
E, et al. TREM2 mutations implicated in neurodegeneration impair cell surface 
transport and phagocytosis. Sci Transl Med. 2014; 6: 243ra86. 
68. Xing YH, Yao RW, Zhang Y, Guo CJ, Jiang S, Xu G, et al. SLERT Regulates 
DDX21 Rings Associated with Pol I Transcription. Cell. 2017; 169: 664-78 e16. 





69. Kaya-Okur HS, Wu SJ, Codomo CA, Pledger ES, Bryson TD, Henikoff JG, et al. 
CUT&Tag for efficient epigenomic profiling of small samples and single cells. 
Nat Commun. 2019; 10: 1930. 
70. Stein CA, Hansen JB, Lai J, Wu S, Voskresenskiy A, Hog A, et al. Efficient gene 
silencing by delivery of locked nucleic acid antisense oligonucleotides, 
unassisted by transfection reagents. Nucleic Acids Res. 2010; 38: e3. 
71. Soifer HS, Koch T, Lai J, Hansen B, Hoeg A, Oerum H, et al. Silencing of gene 
expression by gymnotic delivery of antisense oligonucleotides. Methods Mol 
Biol. 2012; 815: 333-46. 
72. Parker ZM, Murphy AA, Leib DA. Role of the DNA Sensor STING in 
Protection from Lethal Infection following Corneal and Intracerebral 
Challenge with Herpes Simplex Virus 1. J Virol. 2015; 89: 11080-91. 
